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Historical aspects
Malignant hyperthermia (MH) has been identified internationally since 1960 
as a clinical pharmacogenetic entity with an autosomal dominant mode of
inheritance. Denborough and Lovell reported in a letter to the editor of
the Lancet on a well known case of a 21 years old student with a family history
of unexplained deaths during anaesthesia 1. At least ten family members had 
suffered an adverse reaction to anaesthesia in which ether was used. In this 
case the anaesthesia was performed with halothane, “a relatively new volatile
anaesthetic”; the young man barely survived.
Clinical events of perioperatively occurring hyperthermia or hyperpyrexia have
been observed and recorded, and even associated with a familial relationship;
but, unfortunately, never published before 1960 2. MH has undoubtedly been 
a cause of anaesthetic mortality and morbidity since the introduction of diethyl
ether and chloroform into regular clinical practise in the mid-nineteenth century.
Early reports on perioperatively elevated body temperature came from several
surgeons during the first decades of the 20th century. General recommendations
such as to provide good air-circulation during hot weather, not to cover the
patient completely, restrict duration of the operation (and the general anaes-
thesia) and monitor the body temperature, were the result of the anaesthesia
meetings at that time. A specific syndrome, composed of hyperthermia, tachy-
cardia and tachypnoea during anaesthesia, was described for the first time by
Burford in 1940 3. He supposed that the syndrome could be provoked by the
administration of ether.
In the years after 1960 other cases were reported with the interesting 
observation that some patients developed muscular rigidity. This typical adverse
reaction to anaesthesia became known as “malignant hyperthermia”, because 
in those days 70-80% of the patients died shortly after a steep and rapid rise 
in body temperature.
Two groups, one working in Melbourne, Australia and the other in Johannesburg,
South-Africa, independently concluded that the clinical signs of an MH reaction
could be converted into an underlying muscle disease 4,5. Denborough from
Melbourne proved that succinylcholine and halothane had induced severe
rhabdomyolysis in a patient, whose serum creatine kinase (CK) activity rose to
20.500 IU/l, 24 hours after anaesthesia. And in the same year, 1970, Isaacs from
Johannesburg observed abnormally high serum CK activities in relatives of patients
9
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with an MH reaction. Studies of isolated muscle specimens in vitro showed that
muscle fibres from MH patients and normal individuals differ in their limits of
induced tension, when exposed to incremental doses of caffeine and halothane6,7.
It was not until 1984 that a well defined, uniform diagnostic in vitro test became
available. The European MH Group was set up, followed shortly by the formation
of the North American MH Group, setting of laboratory standards led to two
essentially similar protocols for the caffeine and halothane in vitro contracture
test (IVCT) 8,9.
In 1968 it became clear that certain inbred strains of pig were also susceptible 
to MH. Pigs, given anaesthesia with halothane for experiments, developed 
convulsions, fever and finally died 10. It has been known that pigs could respond
to stress with muscle rigidity and high fever. The stress-induced death in pigs
(porcine stress syndrome) had world-wide economic consequences because acute
stress prior to slaughter, resulted in a dramatic devaluation in the quality of pork.
This animal model was to the researchers’ advantage leading to a better under-
standing of MH and has since been serving as a favourable research tool 11.
Clarification of the underlying pathogenesis of MH was made possible by
physiological and biochemical studies and genetic linkage analysis. The latter
made a DNA-based diagnosis of susceptibility to MH possible under specific 
circumstances 12.
Clinical presentation of MH
The term malignant hyperthermia referred originally to a syndrome with a 
mortality rate of 70-80%, where pyrexia was the most impressive clinical feature.
This classical fulminant presentation of hypermetabolism is nowadays rarely seen.
There is no symptom or sign that is unique to MH, and MH is not one entity 13.
MH is a spectrum of disorders, ranging from a life-threatening crisis to none
or an atypical reaction to anaesthesia. The diagnosis depends on the combination
of clinical signs and laboratory abnormalities during or after trigger anaesthesia
(table 1), with reference to the timed sequence of events, concomitant drug
administration and environmental factors. The clinical signs fall into two distinct
categories, metabolic and muscle in origin. The patients showing variants of MH
can be grouped into five types of clinical presentation:
1 Fulminant MH.
2 Moderate or mild MH.
3 Masseter muscle rigidity.
4 Unexplained anaesthetic death or cardiac arrest.
5 Atypical presentation.
Ad 1 Fulminant MH
Fulminant or classical MH is the anaesthetist’s nightmare. It is a life-threatening
crisis, characterized by elements of hypermetabolism in association with res-
piratory and metabolic acidosis and signs of increased permeability of skeletal
muscle cells. Early signs are tachycardia and arrhythmias, in combination with
tachypnoea and hypercapnia. Generalised muscle rigidity can be seen, especially
masseter muscle spasm following the administration of succinylcholine. When
10
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metabolic demands outstrip muscle blood supply, the ischemic picture deteriorates
with desaturation and increasing body temperature; up to 1°C every 5 minutes.
Laboratory abnormalities include: hyperkalemia, increased creatine kinase
activity (CK peaks at 12-24 hours after the ‘metabolic storm’), myoglobinuria, 
combined respiratory and metabolic acidosis, usually with an arterial base 
excess more negative than -8 mEq/l.
Late signs are features of renal failure, disseminated intravascular coagulopathy
and cerebral oedema, often causing death. Fulminant MH requires very active
treatment (see further: clinical management of MH).
Ad 2 Moderate or mild MH
This group is characterised by a less rapid development of signs and does not
appear life-threatening. A variety of metabolic changes occur and muscle anomalies
are mild or absent. The treatment required includes the withdrawal of trigger
agents and often a single dose of dantrolene will be sufficient to normalize 
physiological values. Nevertheless substantial muscle breakdown (manifest by
significant increase in CK) can cause oedematous and tender muscles for several
days, or sometimes even weeks afterwards in moderate MH.
The classification into moderate or mild MH is arbitrary. 
Ad 3 Masseter muscle rigidity
Masseter muscle rigidity (MMR) is probably the most common manifestation of MH.
It is a condition where a patient’s mouth can barely be opened despite great
effort. MMR is a subjective sign and difficult to define.
11
Contraindicated, trigger agents
Volatile anaesthetics
- Ether
- Halothane
- Enflurane
- Isoflurane
- Desflurane
- Sevoflurane
Depolarising muscle relaxants
- Succinylcholine
Safe agents
Amide/ester local anaesthetics
Benzodiazepines
Barbiturates
Propofol
Etomidate
Ketamine
Opioids
Non-depolarising muscle relaxants
- Pancuronium
- Vecuronium
- Rocuronium
- Atracurium
- Mivacurium
(Nor) Adrenaline
Digoxin
N2O
Xenon
table 1 Drugs used in anaesthesia according to their potential for triggering MH in susceptible
patients 13.
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The reduced mouth opening and increased jaw muscle tension for around 
90 seconds is an agonist effect of succinylcholine. This “myotonic” reaction peaks
as fasciculations stop 14. It may occur as a normal, but exaggerated response to
succinylcholine, especially in children. Isolated MMR has been reported in 0.5 to
1% of cases after induction with volatile anaesthetics and an intubating dose of
succinylcholine, in which none of the patients developed MH in spite of conti-
nuation of anaesthesia with the volatile agents 15. 
In modern anaesthetic practise it is considered that MMR should be seen 
as a warning sign of MH, preceding other signs by a considerable period of time. 
The incidence of MH susceptibility (MHS) for patients showing MMR with evidence
of muscle involvement (gross increase in serum CK and myoglobinuria) or with
signs of hypermetabolism, is considerably higher than for patients with MMR
alone (table 2) 13, 16.
Ad 4 Unexplained anaesthetic death or cardiac arrest
This group contains a modest amount of probands, often with historical 
or badly documented anaesthetic incidents of cardiac arrest and/or unexplained
death.
The incidence of MH susceptibility among family members is 66% (table 2) 16.
Further information sometimes reveals a myopathy (i.e. Duchenne muscular dys-
trophy) associated with cardiac arrhythmia and cardiac arrest in the recovery room
after an uneventful anaesthetic with halothane 13. If the cause cannot be turned
up, close relatives should be tested for MH susceptibility.
Ad 5 Atypical presentation
The most widely atypical presentation of MH is postoperative fever. It has been a
common indication for IVCT, but no longer requires screening for MH susceptibility,
despite dramatic case descriptions of patients being packed in ice et cetera.
Referrals for unexpected postoperative renal failure or voiding of brown urine
produced by myoglobin, however, do require diagnostic investigation. These signs
are highly indicative of myopathies or MH 13.
12
Type of clinical presentation nr. of patients incidence of MHS (%)
1 Fulminant 41 96
2.1 Moderate 56 88
2.2 Mild 77 14
3.1 MMR & muscle involvement 83 76
3.2 MMR & hypermetabolism 46 56
3.3 MMR alone 59 28
4 Unexplained anaesthetic
death or cardiac arrest 11 66
5 Atypical presentation 63 7
table 2 Probability of MH susceptibilty in the different types of clinical presentation, derived from
diagnostic investigation and classification of 436 probands using IVCT in Leeds, UK. MMR:
masseter muscle rigidity.
proefschrift_q4  07-09-2004  09:37  Page 12
Clinical grading scale
Out of the desire to create a clinical definition for MH, a group of international 
MH experts developed a standardised clinical case definition that determines the
qualitative likelihood that an adverse anaesthetic reaction represents true MH,
using the Delphi method 17. The ‘clinical grading scale to predict MH susceptibility’
assigns points for abnormal signs and laboratory findings observed during the
adverse reaction. These points are summed to produce a raw score (table 3). The
raw score is converted into an MH rank (D1 to D6) which reflects the likelihood
that the reaction represents MH.
The MH clinical grading scale is recommended for use as an aid to the objective
definition of MH but it has important limitations. The MH likelihood may be under-
estimated if indicators are missing because the anaesthesia provider failed to use
appropriate monitoring or failed to obtain key laboratory data (e.g. CK). Lack of
knowledge concerning the family’s medical history is another reason for under-
estimation. Thus the calculated rank should be viewed as the lower boundry of MH
likelihood and if important clinical information is missing, one should consider not
to use the MH clinical grading scale.
Clinical management of MH
Early recognition and speedy intervention is vital for the successful treatment of
MH. A clear intervention protocol should be available and operating room teams
should practise the emergency MH protocol at training sessions.
Dantrolene rapidly reverses an MH episode 18. Dantrolene is lifesaving; no general
anaesthesia with trigger agents should be given without ready access to 36 vials
of dantrolene; this recommended quantity is theoretically sufficient to treat an
average patient with a total dose of 10 mg/kg.
Treatment of an MH reaction
Stop all triggering agents immediately, inform the surgeon and call for help.
Continue anaesthesia with safe agents if surgery cannot be stopped (table 1).
Hyperventilate with 100% O2, use high fresh gas flow to obtain a normal PaCO2,
replace tubing and CO2 absorbent after the patient is stabilized (replacing respi-
ratory tubing and/or anaesthesia machine during an MH emergency can easily
lead to extra complications). Administer dantrolene 2.5 mg/kg intravenously, 
and repeat every five minutes in doses of 1-2 mg/kg up to a total of 10-20 mg/kg
until all signs are normalised. Aids to facilitate the dissolution of dantrolene will
require the full time efforts of two to three people!
Prompt dantrolene injection is the cornerstone of effective MH therapy
and should have absolute priority next to withholding triggering agents 18.
Symptomatic treatment should be focussed on treatment of hyperkalemia 
and acidosis since these may cause dysrhythmias and cardiac arrest during MH.
The heart muscle is not directly involved in MH pathology. If treatment of hyper-
kalemia plus acidosis does not treat dysrhythmias adequately, lignocaine or 
ß-receptor antagonists can be given. Calcium channel blocking drugs should 
be avoided since they can cause an increase in hyperkalemia and myocardial
depression in the presence of dantrolene 19.
13
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Fluid replacement and volume expansion are neccesary to compensate 
for fluid loss in damaged muscle. Urinary output must be kept high in order 
to prevent renal failure caused by myoglobin precipitation in the tubules.
14
Process Indicator Points
I Rigidity Generalized muscular rigidity 15
Masseter musclerigidity following succinylcholine 15
II Muscle breakdown CK activity > 20000 iu/l following succinylcholine 15
CK activity > 10000 iu/l without succinylcholine 15
Brown colored urine 10
Myoglobin in urine > 60 µg/l 5
Myoglobin in serum > 170 µg/l 5
K+ in serum > 6 mmol/l 3
III Respiratory acidosis EtCO2 > 7.5 kPa during controlled ventilation 15
EtCO2 > 8.0 kPa during spontaneous ventilation 15
PaCO2 > 8.0 kPa during controlled ventilation 15
PaCO2 > 8.5 kPa during spontaneous ventilation 15
Inappropriate hypercapnia 15
Inappropriate tachypnoea 10
IV Temperature increase Inappropriate rapid increase 15
Inappropriate increased temperature > 38.8°C in 
the perioperative period 10
V Cardiac involvement Inappropriate sinus tachycardia 3
Ventricular tachycardia or ventricular fibrillation 3
VI Family history Determined MHS in relatives of first degree 15
Determined MHS in relatives not of first degree 5
Various indicators Arterial base excess < -8 mEq/L 10
Arterial pH < 7.25 10
Rapid metabolic reversal with dantrolene 5
History of adverse anaesthetic reaction and determined MHS in relatives 10
Resting elevated CK and determined MHS in relatives 10
Per process (I-VI): count only the indicator with the highest score; ‘various indicators’ should be added
without regard to ‘double counting’.
Raw score range MH rank Description of likelihood
0 D1 Almost never
3-9 D2 Unlikely
10-19 D3 Somewhat less than likely
20-34 D4 Somewhat greater than likely
35-49 D5 Very likely
50+ D6 Almost certain
table 3 MH clinical grading scale; clinical indicators for use in determining an MH raw score, 
which can be translated to an MH rank (D1-D6) and a qualitative likelihood that an 
adverse anaesthetic reaction represents MH 17. 
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A core temperature above 38.5°C should be treated promptly by infusion of ice
cold fluids and surface cooling (using heat exchange or cooling blankets and 
ventilators). Surface cooling with ice alone is not recommended; bladder and 
gastric lavage provides only a small cooling effect, is time consuming, inconven-
ient and should therefore be avoided. Cooling should be stopped at 38°C to avoid
hypothermia. Guidelines for the treatment of an MH reaction are summarized
in table 4.
Time is of the essence and morbidity is correlated with the duration of symp-
toms. After a timely administration of dantrolene, following early diagnosis, little or
no supportive therapy is necessary. The need for supportive therapy is directly, per-
haps exponentially, proportional to the delay in diagnosis and the institution of
treatment. In the treatment of MH, it must be emphasized that although we have the
knowledge and the ability to diagnose and treat an MH reaction, deaths still occur.
15
I Immediate actions
1 Stop all triggering anaesthetic agents, inform the surgeon and call for help. If possible stop surgery,
continue with safe agents if surgery cannot be stopped.
2 Hyperventilate with 100% O2, use high flow of fresh gas to obtain a normal PaCO2.
3 Administer dantrolene 2.5 mg/kg intravenously, and repeat every 5-10 minutes until all signs 
normalize, up to a total dose of 10 mg/kg.
II Supportive actions
4 Give (iced) saline or Ringer solution intravenously.
5 Correct any acidosis, give NaHCO3 2 mEq/kg; follow arterial bloodgases.
6 Check bloodgases, CK, electrolytes and glucose.
7 Treat hyperkalaemia with insulin and glucose.
8 Monitor temperature; start surface cooling above 38.5°C. Stop cooling at 38°C.
9 Place urinary catheter to monitor urinary output (and colour), maintain output > 1 ml/kg/h with i.v. 
infusions, mannitol and furosemide.
10 Treat cardiac arrhythmias if persistent using lignocaine or ß-receptor antagonists.
III Post emergency actions
11 Transfer to ICU when stable, observe for 24-48 hours; monitor for recrudence and late complications.
12 Administer iv. dantrolene 1-2 mg/kg every 6 hours or continuous infusion 0.25-0.5 mg/kg/h, according
to clinical and metabolic signs.
13 If the MH reaction is complicated with coagulopathy and/or high intracranial pressure that do not
respond to ‘standard’ MH treatment, specific treatment should be given.
14 Obstructive tubular renal failure caused by myoglobinuria usually recovers following a period of
dialysis.
15 After the immediate crisis, warn the patient and their families of the implications of MH and the
necessity of confirming the clinical diagnosis by IVCT.
16 Counsel; refer the proband (or close relatives when the index case deceased) to an MH investigation
unit (http://www.emhg.org).
table 4 Guidelines for the treatment of an MH emergency. The different phases of MH treatment
resembles a three staged rocket.
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Dantrolene
Dantrolene for intravenous administration is distributed as Dantrium by Procter
& Gamble. The 70 ml glass bottle contains 20 mg dantrolene powder (lyophylized
dantrolene sodium: 1-{[5-(p-paraphenyl)furfurylidence]amino}hydantoine), 3.0 g
mannitol (which improves the solubility) and sodium hydroxide to raise the pH to
9.5 when the recommended volume of 60 ml of sterile water is added to dissolve
the powder into a clear yellow/orange solution 18. Dantrolene is highly lipid soluble,
but extremely poorly soluble in water. Precious time can be saved by warming 
the sterile water (or store it in a operating room warming cabinet). Dantrolene
solubility increases linearly with increasing temperature of the diluent between
the recommended “room temperature” of 18-20°C to 40°C (maximum!); time to
achieve a clear solution are respectively 180 and 30 seconds when shaking the
vials thoroughly 20.
The primary pharmacological action of dantrolene is the relaxation of skeletal
muscle. Administration of 2.4 mg/kg body weight dantrolene results in 75%
depression of muscle twitch response. The elimination half-life of dantrolene is 
12 hours; it is partly metabolized in the liver. Dantrolene and its metabolites are
excreted in both the urine and the bile. Residual dantrolene concentrations in the
blood are high enough to give patients a feeling of weakness for up to 48 hours
after the initial dose (2-2.5 mg/kg) 21.
The relaxant action of dantrolene is unusual and still incompletely defined.
Dantrolene causes skeletal muscle relaxation by either direct or indirect inter-
action with the ryanodine receptor, the primary calcium release channel in the
sarcoplasmic reticulum membrane, involved in excitation-contraction coupling.
Mainly due to inhibition of the ryanodine receptor via specific binding sites, the
continued calcium release is supposed to be terminated 18, 22. The myoplasmic free
calcium will return to resting concentrations, permitting relaxation of the muscle,
reversion to a normal metabolic state and termination of the MH syndrome. 
Epidemiology of MH
The incidence of MH is estimated to be 1 in 10.000 to 1 in 15.000 general anaes-
thetics. This generally agreed, but rather high incidence has been calculated in an
early extensive survey of MH published in 1970 23. True incidence of MH is
unknown because it depends on several factors: the definition of clinical MH, the
age and sex of the population studied, the anaesthetic technique and drugs used
for anaesthesia, and the kind of surgery and proportion of emergencies in the 
population studied. Over the past 25 years, the incidence of fulminant MH is
approximately 1 in 225.000 anaesthetics and 1 in 65.000 general anaesthetics
when trigger agents are used 24-26. Mild forms of MH have an incidence of 1 in
4500 anaesthetics with trigger agents 25.
An MH reaction can occur regardless of human race, gender or age. However
the majority of dramatic fulminant MH episodes happen to young fit male adole-
scents 27. MH susceptible probands are most commonly seen in the 10-30 age
group, in a male:female ratio of 2:1.
The predominance of occurrence of an MH reaction during emergency anaesthesia
and anaesthetics for minor surgical procedures (ear nose throat (ENT), eye and
minor orthopaedic surgery) can be explained due to the fact that in these cases
16
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trigger agents are frequently used. This explanation is more plausible than the
association of respectively ENT, eye and musculoskeletal abnormalities with MH.
In recent years the incidence of clinical MH has decreased because less trigger
agents are used. Total intravenous and regional anaesthesia is performed with
‘safe agents’ that do not elicit MH (table 1). Nowadays the combination of
succinylcholine and a volatile anaesthetic, which seem to potentiate each other 
in triggering MH, is rarely being used. This contributed greatly to the decreasing
incidence of MH-reactions.
Pathophysiology of MH
Clarification of the pathogenesis of MH was made possible by physiological and
biochemical studies and genetic linkage analysis. In 1960 the MH syndrome,
characterized by high fever and muscle contractures was distinguished as a 
pharmaco-induced syndrome in humans that could lead to death. The recognition
of a corresponding condition in swine, leading to stress-induced deaths, was
responsible for the fast progression in the elucidation of the pathophysiology
of MH 28.
The most marked sign of acute MH is skeletal muscular rigidity. The rigidity
appears not to be a regular form of muscle contraction but rather a pronounced
contracture. Increase in heart rate, end tidal CO2 and body temperature reflect the
accelerated rate of energy metabolism. This increase in metabolism represents an
attempt to produce ATP at a rate sufficient to counteract the rate of ATP hydrolysis
by actin-myosin ATPase of the contractile apparatus in skeletal muscle fibres.
Skeletal muscle accounts for approximately 40% of the body mass. Once triggered
into a hypermetabolic state, a ‘whole body relative ischemia’ develops in which
excessive metabolic demands exceed the capacity of the body to provide substrate
and O2 ( figure 1). Oxygen saturation and PaO2 decrease and lactate concentration
increases due to glycolysis. If the MH crisis is not actively treated, the syndrome
becomes irreversible. When the ATP concentration reaches one-half of the resting
concentration, breakdown of the mitochondrial membrane occur and the integrity
of the muscle cell membrane alters (rhabdomyolysis); as ATP is essential for the
activity of the enzymes normally involved in the repair and maintenance of cell
membranes. Mg2+, Ca2+, K+, inorganic phosphate and larger molecules and 
proteines such as myoglobin move into the extracellular space and plasma. 
The progressive efflux of potassium ions from the sarcoplasm, together with 
generalized hypoxia, lactate acidosis and elevated concentrations of circulating
catecholamines provoke arrhythmias and impaired cardiac function. Hyperkalaemia
causes ventricular fibrillation, cardiac arrest and ultimately, death.
Rhabdomyolysis may cause visible pigmenturia as a result of the presence of
myoglobin in urine. A major threat of myoglobinuria is acute renal failure due to
renal ischemia and tubular injury.
The crucial role in the pathogenesis of MH is elevated myoplasmic Ca2+. 
Ca2+ regulates contraction, relaxation and energy metabolism in skeletal muscle
cells. It is now clear, from 50 years research of the structure and function of
subcellular components involved in excitation-contraction coupling and skeletal
muscle function, that drugs (e.g. caffeine) can act on the activation site of the 
sarcoplasmic reticulum Ca2+ release channel by increasing the affinity for Ca2+. 
17
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In this way the sensitivity for Ca2+ release is increased 29-31.
When skeletal muscle fibres are stimulated at the motor end plate, the action
potentials travel along the surface membrane and enter the transverse T-tubule
system. The depolarisation signal is transmitted at specialised junctions to the
terminal cisternae of the sarcoplasmic reticulum (SR). Ca2+ is released from the 
SR and the muscle contracts in response to this Ca2+ through the established
interaction of actin, myosin, and troponin (figure 2).
The junction between the T-tubule system and the SR consists of two receptor
complexes: a dihydropyridine receptor (DHPR) complex in the T-tubule membrane
and the ryanodine receptor (RYR) in the SR membrane (figure 3). The coupling
between these two calcium channels is not fully elucidated, although several
structural characteristics and functional mechanisms are known 29-30. The DHPR 
is a slow (L-type) voltage-sensitive calcium channel, comprised of five subunits
(α1, α2, β, γ and δ). The α1-subunit consists of six transmembrane loops, forming
four ion selective pores. The RYR acts as a single Ca2+ release channel when it is
activated. The relatively small hydrophobic part of the RYR forms a transmembranetic
SR baseplate; the huge hydrophilic cytoplasmic domain bridges the gap between
the SR and the T-tubule. This cytoplasmic region, corresponding to the often called
‘foot structure’ of the RYR, contains binding sites for various activating ligands 
like calcium, ATP, calmoduline, caffeine, ryanodine and inositol trisphosphate
(IP3), and for inactivating or modulating ligands like dantrolene and calcium, 
magnesium or ryanodine in high concentrations (> 100µM).
18
actin-myosin filaments
mitochondrion
Ca2+Ca2+  -ATPase
glycogen
transverse tubule
phosphorylasekinase   pyruvate   
DHPR
RYR    
rigidity
heat
CO2
lactate
CO2O2
ATP ADP
ATP ADP
sarcoplasmic reticulum    
figure 1 A proposed mechanism for induction of MH
The release of Ca2+ is the end result of a cascade of events from depolarisation of nerve,
muscle, transverse tubular membranes, and sarcoplasmic reticulum. Abnormalities in the
Ca2+ release channel of skeletal muscle sarcoplasmic reticulum cause continued presence of
Ca2+ within the cell. Sustained muscle contracture accounts for all of the symptoms of MH:
rigidity, and the generation of heat, CO2, and lactate by the sustained glycolytic and aerobic
metabolism.
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Ca2+
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figure 2 Muscle contraction is regulated by cytoplasmic Ca2+ concentrations.
In a normal relaxation-contraction cycle, Ca2+ is pumped into the sarcoplasmic reticulum by
a Ca2+-ATPase to initiate relaxation, stored within the lumen, and released through a Ca2+
release channel to initiate contraction.
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The mechanism, for excitation-contraction coupling linked Ca2+ release by skeletal
muscle which is widely accepted, is the mechanical or direct coupling hypothesis.
The direct coupling hypothesis suggests that the DHPR is the voltage sensor which
transduces a conformational change in the foot structure of the RYR, thereby
regulating the opening of the calcium efflux channel, allowing the release of
Ca2+ into the cytoplasm. The DHPR is directly linked to RYR in skeletal muscle 
for the purpose of controlling SR Ca2+ release and contrary to its function in 
other tissue, it does not act as a channel for Ca2+ uptake by skeletal muscle.
In summary, excitation-contraction coupling is believed to be mainly a
mechanical mechanism, modulated by various cytoplasmic accessory proteins
(calmodulin, FKBP12) and integral membrane proteins (triadin, junctin), 
influencing the activity of the RYR 30 (figure 4).
Genetics of MH
Alterations in the kinetics of calcium release appeared to play a crucial role in MH.
This fact led investigators to study the skeletal muscle sarcoplasmic reticulum (SR),
since the SR had been known to be a site of calcium storage and release 29. The
calcium efflux of the SR is controlled by the ryanodine receptor (RYR), named after
the neutral plant alkaloid and muscle relaxant ryanodine. Ryanodine binds with
high affinity to the calcium release channel of skeletal muscle and is able to
enhance calcium release from the SR 32. RYR has three isoforms, the RYR1 is
believed to be the principal form in adult skeletal muscle, the RYR2 in cardiac 
and the RYR3 in non-muscle 33.
Molecular cloning of the RYR cDNA from human skeletal muscle allowed the
detailed structural analysis of one of the largest known proteins within the cell
(2.200 kDa corresponding to 5.000 amino acids encoded by 106 exons) 34, 35. It
appeared from investigation on the Ca2+ release channel from MH susceptible and
normal pigs that structural alterations in the release channel (RYR1) were involved
in porcine MH 36. Detailed DNA sequence analysis of the RYR1 cDNA from these 
normal and MHS pig skeletal muscle revealed a C to T point mutation at position
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transverse tubule
cell membrane
SR- membrane
Ca2+
DHPR
RYR
ATP ADP
figure 3 Proposed arrangement of the protein complexes in the transverse (T) tubule and sarcoplasmic
reticulum (SR-) membranes.
One tetrad of four dihydropyridine receptor complexes (DHPR) is physically apposed to every
other ryanodine receptor (RYR), the sarcoplasmic reticulum Ca2+ release channel.
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1840, resulting in the substitution of cysteine for arginine in position 614 37. Dito
linkage has been established in studies of inheritance in human families, sug-
gesting 1840C>T as a candidate mutation causing MH in patients where the dis-
ease maps to the RYR1 locus on chromosome 19q13.1 38, 39. However this 1840C>T
(“pig”) mutation was found to co-segregate with MHS in only 3-6% of MH-sus-
ceptible families 40,41. Attempts to identify other mutations in the human RYR1
gene potentially causative for MH susceptibility have therefore been undertaken
(table 5) 42-66. Until now 22 point mutations in the RYR1 cDNA have been found to
correlate with the MHS phenotype, and have been shown to directly alter RYR1
caffeine or halothane sensitivity at research on functional characterization. By
this, these 22 causative mutations meet the criteria set up by the EMHG for predic-
tive genetic testing (guidelines + appendix, chapter 4) 12. The majority of the
causative mutations appear to be clustered in two hotspots between amino acid
residues 35-614 and 2163-2458; a small number of mutations shows linkage to
central core disease (CCD; vide infra) in addition to linkage to MH-susceptibility
(figure 5). In over 50% of the European MH families linkage has been established
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Ryanodine Receptor
Sarcoplasmic Reticulum
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Voltage
Ca2+
+
Ca2+
Ca2+
Force
 Cytoplasmic Accessory Proteins 
- Calmodulin 
- FKBP12
 Integral Membrane Accessory Proteins 
- Triadin 
- Junctin
 Intraluminal Accessory Proteins 
- Calsequestrin
Cell Membrane
DHP Receptor
figure 4 Diagrammatic representation of the major components of the excitation-contraction 
pathway of skeletal muscle. 
The dihydropyridine (DHP) receptor acts as a voltage sensor for the ryanodine receptor
(RYR). The activity of the Ca2+ release channel (RYR) is influenced by cytoplasmic, integral
membrane and intraluminal accessory proteins.
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to the RYR1 gene 30. In a considerable number of families linkage to chromosome
19 could not be confirmed, pointing to genetic heterogeneity. Alternative loci con-
taining the genes encoding the DHPR subunits, for one, have been identified on
chromosomes 1, 3, 5, 7 and 17 67-71.
MH: relationship to other diseases and syndromes
A number of muscle disorders have been associated with MH due to anaesthetic
complications in the past 72, 73. However, in most cases the muscle-related anaes-
thetic complications did not reflect “typical” MH. More important, with the excep-
tion of central core disease, non of the muscle disorders has been genetically
linked to MH.
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figure 5 Diagrammatic representation of the ryanodine receptor.
The large cytosolic part of RYR bridges the gap between the DHPR in the T-tubule and the
sarcoplasmic reticulum. RYR1 mutations potentially causative for MH-susceptibility (MHS)
and/or central core disease (CCD) have been presented as numbers of the human RYR1, 
representing the positions of the replaced amino acids. At position 614, 2163 and 2458 
two mutations have been described.
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Neuromuscular diseases
In neuromuscular diseases (NMD), the causes of anaesthetic complications depend
on whether the neuromuscular transmission or the excitability of the membrane
or the function of intracellular organelles is disturbed.
Muscle relaxants and potent inhalational anaesthetics, given to patients with 
NMD during general anaesthesia, exert strong effects on their muscles and can
provoke complications like masseter muscle rigidity or generalized muscle spasms,
rhabdomyolysis, elevated core temperature, tachycardia or cardiac arrest 74.
Moreover, postanaesthetic complications have been described: weakness or 
prolonged paralysis of skeletal muscle leading to respiratory failure or apnoea.
Most NMD are associated with specific phenotypic features and a specific
genetic mutation, whereas the clinical presentation of MH can be quite variable
and the molecular basis for MH susceptibility is heterogenetic.
NMD which are at risk for adverse anaesthetic reactions are mainly progressive
muscular dystrophies (Duchenne-type, Becker-type, limb girdle- and facio-
scapulohumeral dystrophy), congenital myopathies (Fukuyama-type, centronuclear-
and nemaline myopathy), metabolic myopathies (McArdle’s disease, Brody’s disease,
myoadenylate deaminase deficiency), myotonias (Curschmann-Steinert-type,
Thomsen, Schwartz-Jampel syndrome and myotonia fluctuance), periodic 
paralysis (hyper- or hypokalemic periodic paralysis), myastenia gravis, and a group
of neurogenic disorders (poliomyelitis, spinal muscle atrophy, polyneuropathy).
The halothane-caffeine in vitro contracture test (IVCT) is generally accepted as
the “gold standard” test for the diagnosis of MH susceptibility (chapter 2). The
results of in vitro contracture testing in patients with various NMD are misleading
75, 76. Although the IVCT result can be positive in patients with NMD, the inconsis-
tent minor IVCT contractures reflect the diseased muscle rather than MH 76-78. In
fact positive results (MH-susceptible or MH-equivocal) in patients with NMD could
explain the specificity of 93.6% 79. In vitro sensitivity to the test drugs will not
automatically correspond with an increased in vivo sensitivity. Nevertheless, 
from a practical point of view and/or just to be safe, a patient with a NMD that
is tested MHS or MHE should never get anaesthesia with trigger agents. In all
probands that have had a “serious” adverse anaesthetic event, a combination 
of clinical, morphological, genetic and contracture studies should be carried out.
These studies, together with a detailed family study, will make it possible to
identify the etiology.
The King syndrome or King-Denborough syndrome is often mentioned to 
be associated with MH 80,81. However this association is uncertain because the
King syndrome is said to be a recessive trait and patients have typical clinical 
features 82. The only clearly associated muscle disorder is central core disease.
Central core disease
Central core disease (CCD) is a rare, nonprogressive myopathy, which is characterized
by muscle hypotonia, proximal symmetrical muscle weakness, and CK elevation.
Diagnosis is made on the basis of the typical histological central cores of type 1
skeletal muscle fibers83. The inheritance of CCD is autosomal dominant with variable
penetrance. Within families the clinical signs may vary from severe to absent, the
latter individuals having only the MH trait 84. This association led investigators to
23
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Exon Nucleotide Amino acid Phenotype Reference
change substitution
2 103 T > G C35R *) MHS 42
2 130 C > T R44C MHS 43
6 487 C > T R163C *) MHS/CCD 44
6 496 G > A D166N MHS 45
9 742 G>A R248G *) MHS 46
11 982 C > T A328T MHS 47
11 1021 G >A G341R *) MHS 44
12 1201 C > T R401C MHS 48
12 1202 G > A R401H MHS 45
12 1209 C > G I403M *) CCD (MH?) 44
14 1565 A > C Y522S *) MHS/CCD 44
15 1597 C > T R533C MHS 43
15 1654 C >T R552W *) MHS 44
17 1840 C > T R614C *) MHS 40
17 1841 G > T R614L *) MHS 44
39 6349 G > C V2117L MHS 43
39 6377 G > A R2126Q MHS unpub.
39 6387 C > G D2129E MHS 49
39 6487 C > T R2163C *) MHS 44
39 6488 G > A R2163H *) MHS/CCD 44
39 6488 G > C R2163P MHS 50
39 6502 G > A V2168M *) MHS 44
40 6617 C > T T2206M *) MHS 44
40 6617 C > G T2206R MHS 51
40 6640 G > A V2214I MHS 52
44 7038 GAGdel E2347del MHS 52
44 7048 G > A A2350T *) MHS 52
44 7062 C > T R2355C MHS 53
44 7099 G > A A2367T MHS 52
45 7282 G > A A2428T MHS 45
45 7291 G > A D2431N MHS 52
45 7300 G > A G2434R *) MHS 44
45 7304 G > A R2435H *) MHS/CCD 54
45 7304 G > T R2435L MHS/CCD 55
46 7354 C >T R2452W MHS 56
46 7358 T > A I2453T MHS/CCD 57
46 7360 C > T R2454C MHS 51
46 7361 G > A R2454H MHS 55
46 7372 C> T R2458C *) MHS 44
46 7373 G > A R2458H *) MHS 44
71 10579 C > T P3527S rec CCD 58
table 5 Mutations that underly MH susceptibility (MHS) and/or central core disease (CCD) in the genes
encoding the ryanodine receptor (RYR1). *) = 22 mutations that have been shown to directly
alter RYR1 caffeine or halothane sensitivity, by which they meet the criteria set up by the
EMHG for predictive genetic testing.
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establish linkage between CCD and RYR1 85. Mutations in RYR1 lead to poorly regu-
lated Ca2+ release into the skeletal muscle cell; spontaneous Ca2+ release from the
sarcoplasmic reticulum in CCD or massive Ca2+ release triggered by succinylcholine
and/or potent inhalational anaesthetics in MH and CCD.
Heat stroke, exercise-induced or recurrent rhabdomyolysis
Heat stroke and terms such as ‘exertional heat stroke’, ‘heat exhaustion’, ‘exercise-
induced rhabdomyolysis’ or ‘recurrent rhabdomyolysis’ describe situations in which
the core temperature rises to perilous levels (≥40.6°C) and/or patients with recurrent
attacks of rhabdomyolysis. Heat stress, physical activity and/or depletion of salt
and water are important factors that cause clinical features representing different
degrees of severity on a continuum of disordered thermoregulation86. The clinical
25
91 12640 del 9 RQF4214-4216 del CCD 59
95 13909 A>G T4637A CCD+ rods 60
95 13910 C>T T4637I CCD + rods unpub.
95 13913 G>A G4638D CCD unpub.
95 13938 del 6 LS4647-4648 del CCD 59
95 13952 A>C His4651Pro CCD unpub.
96 14002 C>T P4668S MHS 61
100 14378 T>C L4793P CCD 59
100 14387 A>G Y4796C *) CCD+ rods 62
100 14431 G>A A4811T CCD unpub.
100 14473 C>T R4825C CCD 59
100 14477 C>T T4826I MHS 63
101 14558 C>T T4853I CCD unpub.
101 14578 del TTC F4860 del CCD 59
101 14512 C>G L4838V *) MHS 61
101 14578 T>A F4860I CCD unpub.
101 14581 C>T R4861C CCD unpub.
101 14582 G>A R4861H *) CCD 59; 64
101 14588 del 18 4863-4969 del CCD 65
101 14591 A>G Y4864C CCD unpub.
102 14671 G>C G4891R CCD 64
102 14677 C>T R4893W CCD 59; 64
102 14678 G>A R4893G CCD unpub.
102 14693 T>C I4898T *) MHS/CCD 66
102 14695 G>A G4899R CCD 64
102 14696 G>A G4899E CCD 59
102 14717 C>T A4906V CCD 64
102 14740 A>G R4914G CCD 59
102 14741 G>C R4914T CCD unpub.
102 14749 T>C F4917L CCD unpub.
102 14762 T>C F4921S CCD unpub.
103 14818 G>A A4940T CCD unpub.
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picture of heat stroke bears many similarities to MH. For this reason, patients 
with exertional heat stroke were investigated for susceptibility to MH using the
caffeine-halothane IVCT 87-90. Although approximately 30-50% of the heat stroke
patients fulfilled the laboratory diagnostic criteria for susceptibility to MH, 
there were no known personal or family history of anaesthetic problems.
Nevertheless, the high incidence of abnormal IVCT responses suggests that skeletal
muscle abnormalities could be responsible for exertional heat stroke. Recurrent
rhabdomyolysis proves to be the manifestation of a skeletal muscle abnormality
in which a disturbance in calcium homeostasis is the main pathogenetic factor 91.
By the identification of 5 mutations in the ryanodine receptor gene (RYR1) in
patients with exercise-induced rhabdomyolysis, there is claimed to be evidence
that exercise-induced rhabdomyolysis is associated with susceptibiliy to MH 92,93.
Partly due to this overlap, it is recommended that susceptibility to MH is excluded
in patients who have had episodes of exercise-induced rhabdomyolysis, using the
IVCT and genetic mutation screening 92,94.
Neuroleptic malignant syndrome
The neuroleptic malignant syndrome (NMS) is a potentially fatal complication of
the use of neuroleptic drugs (phenothiazines, butyrophenones and thioxanthines)
95,96. Three major clinical signs indicate the presence of NMS: rigidity, hyperthermia
and rhabdomyolysis with elevated CK. NMS, most often, develops over a period of
24-72 hours after oral neuroleptics. Estimations of the frequency of NMS range from
0.07% to 2.20% 97,98. Because of the similarity of some of the clinical features,
and because dantrolene has been used as a successful therapeutic agent in 
both syndromes, NMS has been associated with MH. The most plausible theory
to explain NMS is a neuroleptic-induced alteration of central neuroregulatory
mechanisms (dopamine depletion or blockade in particular). Another hypothesis
could be that NMS is an abnormal reaction of predisposed skeletal muscle to 
neuroleptics. Although abnormal results (MH equivocal) have been found in the
standard-IVCT, the muscular activity in NMS is assumed to be secondary to the
central nervous system abnormality 99. Since no patient with NMS has been
reported to be MH susceptible according to the EMHG protocol, NMS and MH 
are not thought to be (closely) related.
Diagnosis of MH
Diagnosing MH susceptibility in patients who had survived MH reactions or in
members of a family with MH is of critical importance because of the potentially
disastrous consequences of an MH crisis in the future. Numerous invasive and
noninvasive tests to determine the susceptibility of a person to MH have been
described over the years, but few have generally been accepted as valid 13, 100.
Tests on blood
Determination of creatine kinase activity (CK) is an unreliable test for predicting
susceptibility to MH unless the patient belongs to a family in which increased CK
levels have been shown to correlate with in vitro determination of susceptibility
to MH 101, 102. Likewise, no correlation could be demonstrated between
cholinesterase abnormalities and MH 103. 
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Studies on blood cells: erythrocyte tests 104 and platelet tests 105, 106, did not
seem useful for diagnostic purpose. B-lymphocytes offer an interesting cellular
model because expression of RYR1 has been demonstrated in B-cell lines 107, 108.
Intracellular calcium homeostasis in B-lymphocytes from MHS patients differed
significantly from normal controls upon exposure to halothane 109, 110.
Electrophysiological tests
Motor unit counting 111, the tourniquet test in which twitch height was recorded
before, during and after ischaemia 112, measurements of relaxation rates of the
elicited twitch response 113 and investigation of the EMG recruitment pattern of
the hand muscles after halothane and succinylcholine 114, all proved to be of
little use for the diagnosis of MH-susceptibility due to a considerable degree 
of overlap between MHS and normal individuals.
Tests on muscle
Biochemical muscle tests as indicators of susceptibility to MH are considered to 
be limited. ATP depletion 115, increased glycolytic activity 116, increased ratio of
phosphorylase 117, increased activity of adenylate cyclase and cyclic AMP 118 and
reduced or absent adenylate deaminase 119, are parameters of increased sympa-
thetic activity, but not recommended as diagnostic tools because of the lack of
accuracy and specificity.
Histological differences between MHE, MHS and MHN biopsies are reported 120-122.
Abnormalities include muscle fibre hypertrophy or atrophy, internal nuclei, cores,
signs of necrosis and regeneration, and hypercontracted sarcomeres. However,
histology alone does not make it possible to diagnose susceptibility to MH 123, 124.
Exposure of single, skinned muscle fibres to calcium, caffeine and halothane
are described as a diagnostic test 125. These tests still need further evaluation of
diagnostic sensitivity and specificity.
Measurements of intracellular calcium concentrations seems suitable for 
diagnosing MH susceptibility. At first, calcium sensitive microelectrodes were used
on muscle biopsies 126, later on the methods changed to spectrofluorophotometric
determination of free cytosolic calcium concentrations in cultured human skeletal
muscle cells (chapter 3) 127, 128.
The in vitro contracture test using halothane and caffeine on muscle samples
taken at open biopsy has been the best approach for testing for MH susceptibility
since its introduction in 1970 (chapter 2).
Molecular genetic tests
The complexity of the genetics of MH limits the use of molecular genetic techniques
for the diagnosis of MH susceptibility 129, 130. The European MH group have agreed
on guidelines for the diagnostic use of genetic findings (chapter 4).
In vivo tests
Nuclear magnetic resonance spectroscopy (NMR) using 31P has been applied to
measure the energy metabolism in the forearm flexor muscles 131. Results in normal
and MHS individuals showed significant overlap, that made the value of in vivo
31P NMR for the diagnosis of MH risk doubtful.
27
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Microcalorimetric studies in MH susceptible individuals showed no significant
differences compared to normal individuals in heat production upon exposure to
halothane 132. Analogue to this method a metabolic test has been designed in
which intramuscular injection of caffeine and halothane increases local pCO2 in
individuals susceptible to MH but not in controls 133. The latter might become a
minimally invasive alternative test for the detection of susceptibility to MH 134.
Diagnostic procedure
Based on present day knowledge and according to the European IVCT protocol 
and the EMHG guidelines, probands are selected for screening in accordance 
with table 6. If the proband has died then the nearest appropriate relatives are
screened. The lowest age limit for the muscle biopsy is 12-14 years as IVCT results
have been inconclusive below this age. Besides, the amount of muscle removed
(± 1 gram), represents a significant amount in children. Once MH susceptibility is
confirmed screening is offered to each family member. Preferably those individuals
that are related as close as possible to the proband should be screened at first.
Aim and Outline of the Thesis
The aim of this thesis is to study the diagnostic procedures for MH susceptibility,
with special emphasis upon refining the biological diagnostic test and improving
protocols and guidelines for investigation of susceptibility to MH. Diagnosing MH
susceptibility will improve the safety of anaesthesia in the future for MH susceptible
patients and their families, because anaesthetists can provide safe anaesthesia
when they know their patient is susceptible to MH. MH is a detectable and treat-
able condition of which no one ought to die. 
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Proband or index patient
1 Collect clinical information 
2 MH clinical grading scale 
3 Clinical examination
4 Creatine kinase measurement
5 Standard caffeine-halothane IVCT
6 Histological examination
7 Genetic testing for 22 mutations
Optional tests and research:
- Sevoflurane IVCT
- Ryanodine contracture test
- 4-chloro-m-cresol contracture test
- in-vivo metabolic test
- Test on cultured skeletal muscle cells
- Screening for novel RYR1 mutations
- Genetic segregation analysis
Member from an MH family
1 Collect information about the family
2 Family history with a causative mutation
3 DNA test for the MH mutation
4 Standard caffeine-halothane IVCT when 
the mutation is not detected
5 Family with no causative mutations
6 Standard caffeine-halothane IVCT
Optional tests and research:
- Sevoflurane IVCT
- Ryanodine contracture test
- 4-chloro-m-cresol contracture test
- in-vivo metabolic test
- Test on cultured skeletal muscle cells
table 6 Diagnosing susceptibility to MH.
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The introduction contains an historical review, a description of the clinical
presentation, the treatment of MH and its epidemiology, followed by the current
pathophysiological and genetic insights into MH; the diagnostic tests for MH that
have been described over the years, are summarized.
The in vitro contracture test (IVCT) forms the basis of investigation of MH 
susceptibility. Since 1984 the IVCT is performed using the European MH Group 
protocol (chapter 2). The IVCT has an important disadvantage: it is an invasive test.
An alternative, less invasive test for MH susceptibility is offered by using cultured
skeletal muscle cells, obtained by needle biopsy (chapter 3). Critical evaluation of
the procedure for the diagnosis of MH susceptibility in four European MH centres
can be used to refine family screening and to set up a system for quality assur-
ance of all 21 European MH investigation centres (chapter 4). 
Chapter 5 is a review of the investigation of a family following fulminant malignant
hyperthermia.
In the general discussion the items of chapter 1, will be substantiated with
present-day critics (chapter 6).
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Chapter 2
in vitro contracture test
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Introduction
Numerous diagnostic tests to determine the susceptibility to MH have been
described over the years, but the in vitro contracture test (IVCT) has generally been
accepted as “the golden standard” 1. The IVCT determines the sensitivity of freshly
obtained skeletal muscle specimens to caffeine or halothane applied to carboxy-
genated Krebs-Ringer solution at 37°C.
Kalow introduced the use of caffeine for in vitro diagnosis of MH susceptibility
in 1970, and Ellis introduced halothane as a test drug, the following year 2, 3. The
European MH investigation units, forming the European Malignant Hyperthermia
Group (EMHG), agreed upon a standardised protocol in 1984 4. The IVCT protocol
prescribes the way the muscle should be handled after biopsy and in vitro and
how the muscle should be exposed to the test agents. Furthermore, the protocol
contains the diagnostic criteria. Since 1984 the European IVCT protocol had been
revised several times; the current protocol has been published in 1997 5 (appended
at the end of this chapter). The North American MH Group (NAMHG) agreed upon 
a testing protocol in 19896. Both protocols differ in certain points, but correlation
between the testresults is quite good: 84-100% 7, 8.
IVC testing primarily aims at determining the clinical risk of MH reactions. In
the attempt to identify as many patients at risk as possible, the diagnostic criteria 
are established in a way so that sensitivity approaches 100%. This pursuit of
minimising the chance of false-negative results, is inextricably bound up with
loss of specificity. Taking in account that the IVCT is a biologic test with many
variables, the test shows a high sensitivity: 99% for EMHG and 92-97% for
NAMHG, and a satisfactory specificity: 93.6% for EMHG and 53-78% for NAMHG 5,9.
Basic principle
Immediately after excision, the muscle specimen of the vastus group of the thigh is
placed in a (precarboxygenated) physiological Krebs-Ringer solution and transported
to the IVCT-laboratory. Muscle bundles are tied on both ends and attached vertically
in a tissue bath. The bath is filled with Krebs-Ringer solution at 37°C and bubbled
with 5% CO2 in oxygen. The lower end of the muscle bundle is fixed, the other
end is hanging on an isometric force transducer ( figure 1). The muscle bundles are
stretched to optimal length (preload) and viability of the muscle is ensured by
stimulation at a supramaximal voltage (1 ms duration, 0.2 Hz). Before addition of
the test drug, the muscle bundles are equilibrated for a stable resting tension.
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According to the EMHG test protocol, the cumulative static caffeine contracture 
test and the cumulative static halothane contracture test are performed in duplo.
A fresh muscle bundle is used for each test. The “old” dynamic halothane con-
tracture test and the “modern” ryanodine and 4-chloro-m-cresol contracture
tests are optional tests.
In the cumulative static caffeine contracture test, the caffeine is added cumu-
latively to the tissue bath at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, and 32 mmol/l ( figure 2). A
positive reaction is dependent on a contracture force of at least 2 mN at maximally
2.0 mmol/l caffeine (EMHG threshold concentration).
In the cumulative static halothane contracture test, the halothane is added cumu-
latively to the tissue bath at 0.11, 0.22, 0.44 and 0.66 mmol/l (consistent with 0.5,
1.0, 2.0 and 3.0% v/v) ( figure 3). A positive reaction is dependent on a contracture
force of at least 2 mN at maximally 0.44 mmol/l halothane (EMHG threshold con-
centration).
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Muscle Bundle
Stimulation electrodes
Stimulation Unit
5% CO2
95% O2
Temperature Control Unit
Halothane 0,5-3%
Chart Recorder Unit
37o C
Force Transducer
Amplifier
figure 1 The test set-up for in vitro contracture testing.
Muscle bundles are stimulated at 37°C in Krebs-Ringer solution. Isometric contractions are
recorded after the application of caffeine or halothane.
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Three categories result by each test:
- MHS (MH-susceptible): contractures ≥ 2 mN under or at the threshold 
concentrations of caffeine and halothane.
- MHN (MH-normal or not susceptible): normal reactions to both agents.
- MHE (MH-equivocal): only one type of test is abnormal.
- MHEh: contractures ≥ 2 mN under or at the threshold concentrations 
of halothane only.
- MHEc: contractures ≥ 2 mN under or at the threshold concentrations 
of caffeine only.
Contracture test results may be falsely positive due to coincidental changes in
skeletal muscle resulting from neuromuscular diseases 10, 11, non specific muscle
damage secondary to metabolic factors or drug exposure 12, and technical laboratory
errors 13, 14.
The MHE category was introduced to define a group with a possible false positive
or borderline result. For clinical purposes MHE individuals are considered as MH
susceptible.
More specific activators of the skeletal muscle ryanodine receptor have been used 
in the IVCT instead of caffeine: ryanodine and 4-chloro-m-cresol ( figure 4) 15, 16.
Ryanodine is a plant alkaloid that was used formerly as an insecticide. Because 
of its great affinity for the sarcoplasmic reticulum calcium release channel, 
pharmacologists named this calcium release channel: ‘ryanodine receptor’ after 
it. 4-chloro-m-cresol is a preservative that is commonly present in some pharma-
ceutical preparations.
Multicentre evaluation of in vitro contracture testing with bolus administration 
of either ryanodine (1 µmol/l) or 4-chloro-m-cresol (75 µmol/l) for diagnosis of MH
susceptibility, confirmed that both agents can usefully discriminate between MHS
and MHN 17, 18. Ryanodine IVCT and 4-chloro-m-cresol IVCT might be useful to
improve the reliability of diagnosis of MH susceptibility 19. However, both tests
cannot replace the standard caffeine and halothane diagnostic tests. In order to
do that it would be necessary to determine sensitivity and specificity by the
method of Ørding and colleagues 5. Ryanodine IVCT and 4-chloro-m-cresol IVCT
remain optional tests; only for research purposes they can be applied as additional
tests with a view to assign MHE individuals to MH-susceptible or MH-normal.
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figure 2 Example of the static caffeine in vitro contracture test.
Upper trace MH-normal (MHN); lower trace MH-susceptible (MHS). The threshold caffeine con-
centration is reached when the increase in resting (baseline) tension surpasses 2 mN. 
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figure 3 Example of the static halothane in vitro contracture test
Upper trace MH-normal (MHN); lower trace MH-susceptible (MHS). The threshold halothane
concentration is reached when the increase in resting (baseline) tension surpasses 2 mN.
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figure 4 Example of the ryanodine / 4-chloro-m-cresol in vitro contracture test
In this optional IVCT either ryanodine (1 µmol/l) or 4-chloro-m-cresol (75 µmol/l) is added to
the tissue bath. Upper trace MH-normal (MHN); lower trace MH-susceptible (MHS). Onset time
(OT) = the time following administration until the contracture increases; 2T = the time to
achieve a contracture level of 2 mN.
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Abstract
Determination of sensitivity and specificity of the in vitro contracture
test (IVCT) for malignant hyperthermia (MH) susceptibility using the
European MH Group (EMHG) protocol has been performed in some
laboratories but only on a small sample from the combined EMHG.
Thus the purpose of the present study was to determine combined
EMHG sensitivity and specificity of the test.
Methods: Results of IVCT of patients with previous fulminant MH
and normal, low-risk subjects (controls) were collected from 22 centres
of the EMHG. IVCT was performed according to the EMHG protocol.
Patients were included in the study if the clinical crisis had a score 
of at least 50 points with the Clinical Grading Scale. Low-risk subjects
were included provided they did not belong to a family with known
MH susceptibility, they had not at previous anaesthetics developed
any signs of MH, and they did not suffer from any neuromuscular 
disease. For inclusion of both MH patients and low-risk subjects, at
least 1 muscle bundle in the IVCT should have twitches of 10 mN (1 g)
or more. For evaluation of individual tests, only muscle bundles with
twitch heights of 10 mN (1 g) or more were used.
Results: A total of 1502 probands had undergone IVCT because of
a previous anaesthesia with symptoms and signs suggestive of MH. 
Of these, 119 had clinical scores of 50 and above. From these 119 MH
suspected patients and from 202 low-risk subjects IVCT data were 
collected. Subsequently 14 MH suspected patients were excluded 
from further analysis for the following reasons: In 3 patients, the 
suspected MH episode could be fully explained by diseases other than
MH; in 11 MHS patients, IVCT was incomplete (n=1), data were lost (n=3),
or none of the muscle bundles fulfilled twitch criteria (n= 7). Of the
remaining 105 MH suspected patients, 89 were MHS, 10 MHEh, 5 MHEc,
and one MHN. Thus we observed a diagnostic sensitivity of the IVCT of
99.0% if the MHE group is considered susceptible (95% confidence
interval 94.8%-100.0%). Of the 202 low-risk subjects, 3 were MHS, 
5 MHEh, 5 MHEc, and 189 MHN. This gives a specificity of the IVCT of
93.6% (95% confidence interval 89.2%-96.5%).
Conclusion: The IVCT for diagnosis of MH susceptibility in Europe
has a high sensitivity and a satisfactory specificity.
Introduction
Malignant hyperthermia (MH) is a pharmacogenetic disease of skeletal
muscle which is mainly of concern during and following anaesthesia.
Diagnosis of susceptibility to MH may be established using an in vitro
contracture test (IVCT) with halothane and caffeine. Two international
protocols for the performance of such tests have been published, one
by the European MH Group (EMHG) 1, 2 and the other by the North
American MH Group (NAMHG) 3. The two protocols are similar in many
ways, both including a halothane and a caffeine test. They differ in
some details, and apparently these minor differences are enough to
48
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account for some variations in the results of the tests4, 5.
The ability of a test to discriminate between those who have a 
disease and those who are disease-free is measured by the sensitivity
and specificity of the test 6. Sensitivity and specificity are inherent
characteristics of the test and in principle independent of the prevalence
of the disease tested for. The sensitivity measures the proportion of
those with the disease who are correctly identified by the test and 
the specificity measures the proportion of those without the disease
who are correctly called disease-free by the test 6. In both Europe and
North America the threshold between a normal and an abnormal test
result, for reasons of safety, has been deliberately chosen so as to
secure a high sensitivity of the test, well knowing that such a step
will sacrifice specificity.
In a preliminary evaluation of the test results from a few centres
in Europe, the sensitivity and specificity of the test was found to be
100% and 93%, respectively 7. Similar figures have been observed in
some individual European centres 4,8. Apparent false negative results
of the IVCT have been reported9, 10 although it must be questioned if
the cases described are truly false negatives. Other formal studies
have not found evidence of false negative test results 11-13. One of
the problems encountered when determining sensitivity of the IVCT 
is that the symptoms and signs of MH are non-specific. Thus other
diseases and conditions may mimic the clinical presentation of MH 14.
Another problem is that individuals with the MH phenotype may be
anaesthetised with triggering agents without developing clinical
MH 15, 16. Recently, a Clinical Grading Scale was developed by an 
international panel of MH experts for assessment of the likelihood
that any adverse clinical event could be considered to be MH 17. This
grading scale cannot be specific for MH but allows a comparison of
the severity of the observed clinical episode and therefore could help
to categorise patients when it is impractical to describe in detail the
individual case histories.
The European protocol for the IVCT has been published 1, 2, is used
widely and has been upgraded regularly. Thus, viability criteria and
drug concentrations have been specified. Also, a common database
format for recording results has been agreed upon. In the protocol
four tests are required, two halothane and two caffeine tests. The
caffeine tests are static tests performed at optimal length of the fibre
bundle. Concerning the halothane tests, at least one is a static test,
whereas the second may be either a static or a dynamic test in which
the length of the fibre bundle is cyclically changed 18. Few European
centres use the dynamic test at present, and it is not settled if this
test has any advantages compared to the static test 19, 20. However,
more patients in Europe are tested with the dynamic halothane test
than without it because it is used by the Leeds MH centre which is by
far the largest MH centre in Europe.
49
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A patient is considered susceptible to MH (MHS) if at least one
halothane test result and one caffeine test result are abnormal 2. If
the results of all 4 tests are normal, the patient is considered non-
susceptible (MHN). In the case with abnormal test results to either
caffeine or halothane but not to both agents, the result is categorised
as MHE (equivocal) and for reasons of safety most of these patients are
clinically treated as MH susceptible, whereas in genetic investigations
they are assigned unknown disease status.
The present study was initiated to establish combined sensitivity
and specificity of the test on data from many different European centres
applying the viability criteria which are now part of the testing protocol
on individual muscle bundles. For the clinical safety of patients it is
essential to secure a high sensitivity of the IVCT but for research it is
important to estimate the specificity. Such data have hitherto not
been available on a large scale for data obtained with the protocol 
of the European MH Group.
Materials and Methods
All centres performing IVCT in Europe were asked to forward results 
of IVCT in patients considered to have survived fulminant MH, and in
normal, low-risk subjects (controls), using the database format of the
EMHG for reporting results. Patients were assigned a diagnosis according
to the result of the IVCT: MHS (MH-susceptible) if the result of at
least one halothane test and one caffeine test were abnormal; MHE
(MH-equivocal) if either the halothane or the caffeine test result was
abnormal; and MHN (MH-negative) if both halothane and caffeine
test results were normal. Abnormal results of IVCT were those with
increases in muscle bundle force of at least 2 mN (0.2 g) at halothane
0.44 mmol/l or less and at caffeine 2 mmol/l or less. Contracture
thresholds at higher concentrations than these were considered normal.
In order to avoid any bias in the selection of patients we applied
the Clinical Grading Scale 17 to the clinical episodes of the patients
investigated with IVCT because of previous symptoms and signs of MH
during or following anaesthesia. Only those cases with a score of 50
or more (i.e. the patients belonging to group 6 with the most severe
and well-documented reactions) were accepted for inclusion into this
study as fulminant MH cases. The flowsheet for evaluation of patient
data is shown in figure 1.
Normal low-risk subjects (controls) were defined as patients
undergoing surgery who had no symptoms or signs of neuromuscular
disease themselves, and who were not genetically related to any such
patient. If these low-risk subjects had previously undergone anaes-
thesia, it was a condition that no side effects which could resemble
MH had been observed.
An additional criterion should be met by both MH patients and
normal low-risk subjects in order for them to be included into the
study: at least one muscle bundle should have a twitch height of
50
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10 mN (1 gram) or more (figure 1). For analysis of individual tests, only
muscle bundles with twitch heights of at least 10 mN (1 g) were
included because this viability criterion is the one applied in the 
protocol for the IVCT. Thus inclusion into the study was determined 
on 2 levels: a subject level and a muscle bundle level (figure 1).
Patients were excluded if they were found to have another neuro-
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Patient not included
50+ points with CGS?Previous MH in patient or family?
“Fulminants”
Suspected clinical MH  
IVCT
“Controls”
“Healthy” patients from whom 
muscle biopsies were obtained
no yes
no yes
yes
no
no
no
yes
no
yes
yes
Neuromuscular disease present?
Inclusion into the study
Inclusion into the study
Other neuromuscular 
disease explaining MH-like 
symptoms and signs?
Exclusion of patient
Review of IVCT data
At least one muscle bundle 
with twitches ≥ 10 mN (1g)?
Patient data used for analysis
Diagnosis
Sensitivity & specificity
Individual test bundle with 
twitches ≥ 10 mN (1g)?
Exclusion of patient
Data lost / incomplete IVCT?
no yes Single data analysisExclusion of muscle bundle
figure 1 Screening of data submitted for the study.
Flowsheet showing how data were screened for inclusion into the study and at which levels
patients or muscle bundles were excluded. Scoring with the Clinical Grading Scale (CGS) was
performed in individual centres and checked for the patients with 50 points or more by the
first author. See text for further explanation.
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muscular disease which could fully explain the MH-like symptoms
and signs (figure 1). For both MH patients and low-risk subjects,
patients were excluded if data were lost or the IVCT was not complete.
In addition, results from individual muscle bundles were excluded if
the bundle did not fulfill viability criteria (i.e. a twitch height of 10 mN
(1 g)) (figure 1). 
For statistical evaluation, the Mann-Whitney Rank Sum Test and
the Chi-square test were used. Confidence intervals were calculated
for binomially distributed data. P<0.05 was considered significant.
Results
A total of 22 MH centres from 13 countries in Europe participated in 
the project. Altogether, 1502 probands had been investigated with IVCT
in these centres. The 1502 suspected MH reactions were scored accord-
ing to the Clinical Grading Scale 17. The result of this scoring and the
outcome of the IVCT performed in these 1502 patients are shown in
table 1. A significant correlation was found between the category
of the clinical reaction and diagnosis (P<0.001).
IVCT data concerning the 119 patients scoring 50 points or more 
in the Clinical Grading Scale (i.e. group 6 patients with a likelihood 
of MH described as “almost certain”) were collected. In addition, data
were collected from 202 normal low-risk subjects. Results from 14 of
the group 6 patients were subsequently excluded for the following
reasons (see also figure 1): 3 patients were found to suffer from other
neuromuscular diseases; these patients were MHN and their clinical
episodes are reviewed below. In 4 patients the IVCT was incomplete 
(n= 1) or data were lost (n=3) and in 7 patients none of the muscle
bundles for IVCT had twitch heights of at least 10 mN. These 11 patients
were all MHS. Thus, test results from 105 patients with previously
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Category/diagnosis MHS MHEh MHEc MHN Total
1 (0) 4 2 2 21 29
2 (3-9) 4 3 3 24 34
3 (10-19) 161 81 22 474 738
4 (20-34) 118 56 23 214 411
5 (35-49) 96 27 8 40 171
6 (50+) 99 11 5 4* 119
Total 482 180 63 777 1502
table 1 Results of scoring the adverse anaesthetic reaction of all probands investigated for MH using
the Clinical Grading Scale 17, and results of IVCT.
The proportion of individuals in each diagnostic category varies with scoring. Diagnostic 
category and scoring group are significantly related (P<0.001, Chi-square analysis).
*Three of these 4 MHN individuals were excluded from the study because other diseases fully
explained the clinical episode (neuroleptic malignant syndrome in one patient, limb girdle
muscle dystrophy in one, and myotonia fluctuans in one patient) - see text for further details.
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suspected fulminant MH and 202 low-risk subjects were evaluated in
the study. The data finally included in the study originated from 20
centres for MH patients and 14 centres for low-risk subjects. 
Thirteen centres contributed data on both MH patients and low-risk
subjects.
The case histories of the three patients who had scores of 50 or
more in the Clinical Grading Scale, and who were excluded because of
other diseases are summarised below to illustrate the appropriateness
of the exclusion.
Patient 1: A 60 yr old male was anaesthetised for a laparotomy
because of a perforated peptic ulcer. Drugs given during anaesthesia
included atropine, diazepam, thiopentone, droperidol, suxamethonium,
fentanyl, and isoflurane in O2/N2O. The anaesthesia was uneventful.
The following day the patient developed delirium tremens and was
treated with haloperidol. Following this drug, the temperature started
to increase. Within 2 days temperature reached 42°C, the patient
became rigid and myoglobinuria was observed. CK was 20,900 U/l. 
The patient was treated with dantrolene without any effect. Following
symptomatic treatment in the ICU, the condition of the patient slowly
improved during the next month. IVCT (result MHN) was made for a
differential diagnosis of MH and neuroleptic malignant syndrome
(NMS) and the patient is considered to have suffered from NMS. 
Patient 2: A 13 yr old boy was anaesthetised for dental surgery.
Following suxamethonium he developed masseter muscle rigidity,
which did not impede intubation. Anaesthesia was maintained with
53
Anaesthetic N
Halothane 44
Enflurane 12
Isoflurane 45
Other agents 4
Total 105
table 2 Type of anaesthetic agent triggering MH in 105 patients suspected of fulminant MH.
Sign or treatment Yes No Unknown
Suxamethonium 80 23 2
Masseter muscle rigidity 55 38 12
Generalised rigidity 64 24 17
Myoglobinuria 68 11 26
Ventricular extrasystoles 37 32 36
Dantrolene 77 26 2
table 3 The use of suxamethonium, clinical signs, and treatment of MH with dantrolene in 
105 patients suspected of fulminant MH.
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halothane. He became acidotic with an arterial pH of 7.24 and a base
excess of -9. Temperature increased to 38°C. Postoperatively, he had
marked myoglobinuria but no renal failure. CK was 111,740 U/l.
Subsequently resting CK was found to be increased to 1163 U/l. The
patient had no clinical signs of a neuromuscular disease at the time.
IVCT was normal (MHN), but muscle histology was abnormal and 
indicating limb girdle muscle dystrophy. This latent neuromuscular
disease is considered to have caused the anaesthetic problems in 
this patient.
Patient 3: A 16 yr old male was anaesthetised for torsion of the
testis. Rapid sequence induction was performed. Following suxam-
ethonium masseter and generalised muscle rigidity was observed. A
few minutes later oxygen saturation decreased to 26% and end-tidal
pCO2 increased to 12.7 kPa in spite of ventilation with 100% oxygen
and a high flow. Heart rate increased to 120 bpm and temperature to
39.6°C. Arterial blood gases 30 minutes after induction showed acido-
sis with pH 7.09, pCO2 8.9 kPa, and base excess –11.7. The patient was
treated with dantrolene and sodium bicarbonate and recovery was
rapid. Serum potassium remained normal, CK increased to a maximum
of 743 U/l. IVCT was normal. However, the patient was found to suffer
from myotonia fluctuans and a mutation in the sodium channel 
gene on chromosome 17 was identified 21.
Details of the clinical episodes of MH in the remaining 105
patients suspected of fulminant MH are summarised in tables 2-4.
It is apparent that several variables were not measured or reported
for all patients. Some measurements of end-tidal or arterial pCO2 (table 4)
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Mean (SD) Maximum Minimum N
Age (yrs) 21.3 (11.7) 65 1 105
Duration (min) 56.6 (60.9) 360 5 85
Temperature (°C) 39.9 (1.4) 44.0 37.1 100
EtCO2 (kPa) 11.0 (3.6) 28.0 6.3 42
CO2art (kPa) 10.7 (4.8) 32.3 5.3 70
pHart 7.09 (0.15) 7.40 6.60 83
CK (U/l) 29,840 (35,503) 225,000 300 94
K+ (mmol l-1 ) 5.6 (1.2) 8.0 3.1 71
Score 63.5 (9.4) 88 50 105
table 4 Clinical details of 105 patients suspected of fulminant MH.
Age: at the time of the MH crisis; duration: of anaesthesia until MH was diagnosed; 
temperature: the maximum temperature measured during the crisis; EtCO2: maximum 
end-tidal tension of CO2 during the crisis; CO2art: maximum tension of CO2 measured 
during the crisis in arterial blood; CK: maximum concentration of the enzyme creatine 
kinase measured in blood following the crisis; K+: maximum concentration of potassium
measured in blood during the crisis; score: result of application of the Clinical Grading
Scale 17; N: the number of patients in whom a given variable was measured.
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were done during hyperventilation or following other treatments. The
reporting system did not allow details concerning this problem.
Clinical details of the MH patients and low-risk subjects relating
to the muscle biopsy are shown in table 5. The low-risk subjects were
significantly older than the patients surviving MH (Mann-Whitney
test, P<0.001), whereas the sex distribution was similar in the two
groups of patients (P=0.091). A significantly larger proportion of MH
patients than controls had abnormal neurological signs and abnormal
histopathology although histopathology was not performed in the
majority of control patients.
Details relating to the IVCT are shown in table 6 (halothane test)
and table 7 (caffeine test). No significant differences were found
between the two groups for any variables of the IVCT with the exception
of the number and sizes of contractures which were significantly more
frequent and of larger size in the MH group (p<0.001).
Whereas 168 of 181 viable specimens from MH patients developed
a contracture of >2 mN (0.2 g) in the halothane test, only 12 of 272
specimens from low-risk subjects did so (P < 0.001) (table 6). In the
caffeine test, 128 of 143 viable specimens from MH patients developed
contractures whereas only 8 of 258 viable specimens from the low-risk
subjects did so (P<0.001).
From the number of muscle bundles with contractures exceeding
the threshold of 2 mN (0.2 g) at halothane 0.44 mmol/l or caffeine 
2 mmol/l, the false positive or false negative rate of results may
be calculated for the two tests. Altogether 13 of 181 muscle bundles
from MH patients did not develop contractures in the halothane test
(table 6), giving a false negative rate of 7.2% for individual muscle
bundles. The false negative rate for muscle bundles in the caffeine
test was 15/143 (table 7), i.e. 10.5%. The false positive rate for the
halothane test was 12/272 muscle bundles (table 6), i.e. 4.4%, whereas
the false positive rate for the caffeine test was 8/258 (table 7), i.e. 3.1%.
It must be noted that these rates are not for patients, only for
specimens tested. 
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Fulminant Control P value
Sex, m/f/u 67/38/0 106/94/2 0.091
Age, yrs 23.7 (11.6) 51.3 (17.9) < 0.001
(4-66) (7 -90)
Anaesthesia, r/g/u 62/27/16 127/58/17 0.185
Neurology, p/a/u 11/79/15 0/143/59 <0.001
Histopathology, n/a/np 62/18/25 43/0/159 <0.001
table 5 Clinical details relating to the muscle biopsy in 105 patients suspected of MH and 202 low-risk
subjects. Sex: m = male, f = female; anaesthesia for the biopsy: r = regional, g = general, 
u = unknown; abnormal neurological signs: p = present, a = absent, u = unknown;
histopathology: n = normal, a = abnormal, np = not performed.
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Halothane test
Median Mean (SD) Range Nsamples Nindividuals
Twitch (mN) Fulm 35 43 (28) 10 - 132 181 103
Contr 20 24 (15) 10 - 98 272 181
Length (mm) Fulm 18.0 18.9 (5.5) 6 - 33 173 64
Contr 17.0 19.9 (5.1) 6 - 33 231 107
Weight (mg) Fulm 150.0 165.2 (81.8) 49 - 684 127 65
Contr 153.5 156.7 (72.5) 22 - 340 168 98
Contracture Fulm 17 20 (16)* 2 - 89* 168* 99*
(mN) Contr 4 4 (3)* 2 - 12* 12* 8*
table 6 Muscle bundle characteristics in the halothane test for those bundles included in the study
(criterion: twitch heights of at least 10 mN).
Fulm = bundles from patients with a score in the Clinical Grading Scale of 50 and above 
(n = 105 patients). Contr = bundles from low-risk subjects (n = 202 subjects). Nsamples for
twitch are the number of specimens fulfilling viability criteria (twitch height of 10 mN or
above). For length and weight, Nsamples signify the number of specimens fulfilling viability
criteria and for which length and weight were reported. For contracture, Nsamples signify the
number of viable specimens with a contracture of at least 2 mN at halothane 0.44 mmol/l.
Nindividuals signify the number of individuals from whom the Nsamples come. All patients
had at least one halothane test and one caffeine test performed. * P<0.001.
Caffeine test
Median Mean (SD) Range Nsamples Nindividuals
Twitch (mN) Fulm 27 38 (27) 10 -146 143 92
Contr 20 25 (17) 10 -99 258 179
Length (mm) Fulm 18.0 18.2 (5.2) 10 - 32 113 65
Contr 18.0 19.5 (5.9) 5 - 35 172 141
Weight (mg) Fulm 167.5 169.5 (74.8) 47 - 550 112 65
Contr 160.0 155.1 (74.0) 27 - 350 166 130
Contracture Fulm 11 14 (13)* 2 - 62 128* 94*
(mN) Contr 2.8 3 (1)* 2 - 5 8* 8*
table 7 Muscle bundle characteristics in the caffeine test for those bundles included in the study
(criterion: twitch heights of at least 10 mN).
Fulm = bundles from patients with a score in the Clinical Grading Scale of 50 and above 
(n = 105 patients). Contr = bundles from low-risk subjects (n = 202 subjects). Nsamples for
twitch are the number of specimens fulfilling viability criteria (twitch height of 10 mN or
above). For length and weight, Nsamples signify the number of specimens fulfilling viability
criteria and for which length and weight were reported. For contracture, Nsamples signify the
number of viable specimens with a contracture of at least 2 mN at caffeine 2 mmol/l.
Nindividuals signify the number of individuals from whom the Nsamples come. All patients
had at least one halothane test and one caffeine test performed. * P < 0.001.
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Diagnoses resulting from the IVCT are shown in table 8. For reasons
of safety, the MHE group is considered to be at risk of MH. The sensitivity
and specificity of the IVCT are 99.0 % (104/105) (95% confidence interval
94.8%-100.0%) and 93.6% (189/202) (95% confidence interval
89.2%-96.5%), respectively. If the MHE group is omitted from the MH
group, the specificity increases to 98.4% (189/192). However, we have
agreed the MHE groups are under constant review. 
One patient among those categorised by the Clinical Grading 
Scale as fulminant tested MHN in the IVCT. The MH suspected episode
occurred in 1978 and is reported below.
Patient 4: This patient was a 10 month old boy requiring plastic
surgery for cleft palate. The anaesthetic itself was uncomplicated and
included halothane and atropine, but at recovery generalised rigidity
and possibly convulsions were observed. The body temperature was
40.6°C and an arterial blood sample showed a combined metabolic
and respiratory acidosis with pH 7.10 and PaCO2 8.7 kPa. No information
about possible myoglobinuria, plasma increases in CK or K+ were
available. Treatment consisted of oxygen and cooling (the patient had
been on a warming blanket throughout a two hour period in addition
to being wrapped in blankets and completely covered by surgical
drapes). Further recovery was uneventful. The patient had an IVCT
performed in 1989 at the age of 12 years. He looked “peculiar” and
was intellectually somewhat retarded. There was no clinical signs of
neuromuscular disease except for the treated cleft palate. IVCT was
normal. Histology showed fibre type one predominance and centrally
located nuclei but no cores, indicating the presence of a nonspecific
myopathy. Following this result the mother was investigated to rule
out a false negative result of the IVCT. She was also MHN. The father
has refused to undergo IVCT. Thus it is impossible to determine if this
is a false negative result of the IVCT or the episode was due to over-
heating with ensuing convulsions, hypoxia, hypercapnia, and 
acidosis in a patient with a latent myopathy.
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MHS MHEh MHEc MHN N Sensitivity Specificity
Fulm 89 10 5 1 105 99.0% -
(94.8-100.0%)
Contr 3 5 5 189 202 - 93.6%
(89.2-96.5%)
table 8 Diagnostic outcome of the IVCT in 105 patients suspected of fulminant MH and 202 normal
low-risk subjects.
For calculation of the diagnostic sensitivity and specificity of the IVCT, patients with an MHE
diagnosis are considered susceptible to MH, as most would be clinically for reasons of safety.
For sensitivity and specificity 95% confidence limits are given in brackets. If, for calculation
of specificity, the MHS diagnosis is exclusively used, specificity would increase to 98.4%.
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The number of data reported from individual centres were too
small to calculate centre-specific variability and the number of data
were not evenly distributed from the 22 participating centres.
Concerning the MH patients, the 16 non-MHS responses originated from
9 different centres, which does not hint at skewness in distribution.
Likewise, the 13 non-MHN responses in the control group originated
from 6 different centres out of the 14 centres contributing control
data.
With the present large sample of data, it is possible to investigate
the effect on sensitivity and specificity of other thresholds than the
current of 2 mN (0.2 g). In table 9 calculated sensitivity and specificity
are shown for thresholds of 2-5 mN. It is apparent that increases in the
threshold value above 3 mN reduces sensitivity. This is significant for
the 5 mN threshold (P=0.023, Chi-square test with Yates correction). 
A threshold of 3 mN maintains sensitivity and increases specificity.
However, this increase in specificity is not statistically significant
(P=0.25, Chi-square test with Yates correction). In addition data 
are given for different halothane and caffeine thresholds: 0.3 g for
caffeine and 0.5 g for halothane, but this does not improve sensitivity
and specificity.
Discussion
Safety for all patients undergoing anaesthesia is a main goal of
anaesthetists. MH has been one of the severe complications of
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Threshold MHS MHEh MHEc MHN N Sensitivity Specificity
(mN)
Fulm 2 89 10 5 1 105 99.0% -
3 81 16 5 3 105 99.0% -
4 77 16 6 6 105 94.2% -
5 66 24 6 9 105 91.4%* -
Contr 2 3 5 5 189 202 - 93.6%
3 2 3 2 195 202 - 96.5%
4 1 4 1 196 202 - 97.0%
5 0 3 0 199 202 - 98.5%*
Fulm H 5, C 3 77 15 9 4 105 96.2 -
Contr H 5, C 3 2 1 2 197 202 - 97.5%
Values are number of patients within a diagnostic category, given a particular threshold. If nothing is
mentioned the threshold applies to both halothane and caffeine data. The currently used threshold for
both halothane and caffeine tests is a 2 mN contracture with 0.44 mmol/l halothane or less and 2 mmol/l
caffeine or less. * denotes a significant decrease in sensitivity or increase in specificity compared to that
obtained with 2 mN.
table 9 Effect on sensitivity and specificity of different contracture thresholds applied to the IVCT data
presented in this study.
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anaesthesia with an early mortality rate of 70% 22. In recent years, 
the number of deaths from MH has significantly decreased, and in
some countries is now zero 4. Performing IVCT has several purposes:
The main one is to eliminate the threat of MH from all those individ-
uals who do not have the MH phenotype so that they can be anaes-
thetised without any specific precautions and be given volatile
anaesthetics if the anaesthetist wishes to use these agents. Because
MH is an inherited disease, the number of individuals who may thus
benefit from IVCT is large compared to the number of patients who
have themselves developed signs of MH. Another purpose is to estab-
lish a definite diagnosis in those individuals who do have the MH
phenotype and to inform the patients and their attending doctors of
this disease. A research purpose is to establish a link between the
clinical phenotype, the IVCT result, and the presence or absence of the
mutations associated with MH. For this purpose, a systematic analysis
of the clinical signs of MH present during a crisis and the results of
the IVCT must be performed. 
There has been no formal assessment of the Clinical Grading Scale
which was developed by an international panel of MH experts by the
Delphi method 17. It represents an attempt at providing objective 
criteria for classification of clinical MH. For each individual process
involved in MH, points are awarded according to the occurrence of
specific signs, realising that several variables may be signs of the same
process. Thus double-counting is avoided although not completely.
Points may be given for both hypercapnia, low pH, and negative
base-excess, although these parameters are related. Another problem
is that since none of the symptoms or signs of MH are specific, it fol-
lows that the Clinical Grading Scale cannot be specific either. Thus
severe rhabdomyolysis following cardiac arrest during anaesthesia
may give rise to high scores classifying the episode as highly likely to
be MH although nothing points to MH 14, 23. The three patients with
other neuromuscular diseases whom we excluded from the analysis of
IVCT data represent patients with such non-specific high scores. We
find the exclusion of these patients appropriate because it is well-
known that patients with other neuromuscular diseases may develop
signs similar to MH without having the MH phenotype 14. 
The result of scoring is dependent on the quality of documenta-
tion of the case. In this study, some cases of real and severe MH,
mostly occurring many years ago, were not well documented at the
time of the crisis and thus did not obtain a score high enough to be
included. Other cases were well documented and considered to repre-
sent real, fulminant MH in the investigation centre but were excluded
because they did not obtain a score of at least 50. Such cases are 
considered representative of less severe MH, often due to early diagno-
sis and treatment. The fact that we observed a significant correlation
between the score and the proportion of MHS responses seems to val-
idate the usefulness of the Clinical Grading Scale for comparison of
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groups of patients though it should not be used for diagnostic 
purposes for an individual.
The sensitivity of 99% observed in this study is satisfactory for a
diagnostic test, the more so because the clinical adverse event in the
single MHN patient scoring above 50 points may well be due to other
factors than MH. This case illustrates the fact that a definite diagnosis
may not always be established even with use of the invasive IVCT. The
observed sensitivity of the IVCT is comparable to that obtained by the
North American MH Group 24.
The specificity of the IVCT observed in the present study is also
satisfactory, given the high sensitivity and also compared with the
observations made by the North American MH Group 25. However, 
for other purposes than patient safety, it seems wise not to include
patients with the MHE response into the group of MH susceptible
patients. This suggested guideline is supported by the fact that in
families with known chromosome 19 mutations related to MH, MHE
individuals rarely do have the mutation in question 26-28. Thus the
original statement concerning the MHE group, that this group is 
under permanent review, is still valid 2.
Should the critical contracture size be changed from the present
2 mN value? Based on our present rather large data sample there is no 
justification for change. As shown in table 9 only a change from 2 mN
to 5 mN significantly increases specificity, and this occurs at a cost of
a significantly reduced sensitivity which would be unacceptable. The
reason why our halothane threshold contracture is smaller than that
used by the North American MH Group is that our dose-response
curve has cumulative increments in concentration to 2%, whereas the
NAMHG uses a single addition of 3% halothane. The single dose has
previously been shown to result in larger contractures 4.
For clinical decision making it is not enough to know the sensi-
tivity and specificity of the IVCT. What really counts is the predictive
value of a positive or negative response, which depends on the
prevalence of the disease (in this case MH) in the population
tested 4,6. With a very high sensitivity of the test and a somewhat
lower specificity, as presently observed for the IVCT, the predictive
value of a negative test result is around 99%. The predictive value of
a negative result is not much influenced by the prevalence of the dis-
ease when the specificity is as high as that found for the IVCT and it
increases with decreasing disease prevalence4,6. On the other hand,
the predictive value of a positive test result is heavily influenced by
the disease prevalence in the test population. The a priori risk of a
first degree relative of a patient surviving fulminant MH having inher-
ited the disease is 50% and in such a patient the predictive value of a
positive test result is about 90%4. However, if instead a cousin with
an a priori risk of 12.5% is investigated the predictive value of a posi-
tive result of the IVCT is reduced to approximately 50% 4. The predic-
tive value of a negative result in the same patient is close to 100% 4.
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An abnormal result in a member of the general population who has a
very low a priori risk of MH is therefore much more likely to be a false
positive result than indicating MH susceptibility. These considerations
are important when selecting patients for IVCT. The greatest confi-
dence in the results is obtained in those with the highest a priori risk
of susceptibility.
Although data are insufficient to prove that results vary between
centres, it is obvious from tables 6 and 7 that individual test proce-
dures probably could be more standardised. Since data were collected
for this study steps have been taken to standardise muscle length and
weight as well as the size of the preload and the method to obtain
this preload. These guidelines are presented in the updated current
protocol.
In conclusion, the observed sensitivity of 99% and specificity of
93.6% in the IVCT which we have obtained in this joint Europan study
is considered satisfactory for patient safety. For research purposes it is
recommended to increase the specificity to 98% by not regarding MHE
patients as susceptible.
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Contractures in skeletal muscle of malignant 
hyperthermia susceptible patients after in vitro
exposure to sevoflurane
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Abstract 
Sevoflurane, a potent inhalational anaesthetic agent that is structurally
similar to halothane, has some favorable characteristics, but may also
be able to trigger malignant hyperthermia (MH) in susceptible patients.
The diagnosis of malignant hyperthermia susceptibility relies on the 
in vitro contracture test on skeletal muscle. The present study was
undertaken to investigate whether exposure to sevoflurane of muscles
of malignant hyperthermia susceptible (MHS) patients would also cause
an abnormal contracture.
Methods: Muscle fascicles from three MHS patients, one malignant
hyperthermia non-susceptible (MHN) patient, two control patients
and one malignant hyperthermia equivocal (MHE) patient were
exposed to sevoflurane instead of halothane in the in vitro contracture
test, carried out according to the protocol of the European Malignant
Hyperthremia Group. The muscle fascicles were surplus to diagnostic
requirements. Sevoflurane concentrations in the testbath were measured
using a headspace gas chromatographic technique.
Results: The kinetics of sevoflurane concentration in the testbath
were similar to those of halothane. An in vitro contracture response of
2 mN or more was seen in all four MHS/MHE patients with sevoflurane
and not in the three control/MHN patients. The magnitude of muscle
contracture in the sevoflurane test was less than in the conventional
halothane test at comparable testbath concentrations.
Conclusions: Sevoflurane can trigger an abnormal contracture in
human muscle in vitro. This is indicative of malignant hyperthermia
susceptibility. Exposure to sevoflurane should be avoided in patients
thought to be susceptible to malignant hyperthermia. 
Introduction
Sevoflurane is a volatile anaesthetic agent and is used for the induc-
tion and maintenance of general anaesthesia. Unlike other currently
clinically used halogenated inhalational anaesthetics (e.g. enflurane,
isoflurane and desflurane), sevoflurane does not irritate the airways,
causing less coughing and mucous production during induction of
anaesthesia. The blood/gas partition coefficient at 37°C of sevoflurane
is low (0.63-0.69). These characteristics of sevoflurane make it a use-
ful drug for induction of anaesthesia, especially in children, because
of a rapid and smooth induction and a fast recovery.
Potent inhalational anaesthetics can trigger Malignant
Hyperthermia (MH) 1, 2. Sevoflurane is not thought to be an exception.
MH susceptible swine have been exposed to sevoflurane and MH-
reactions did not occur as often as after halothane administration,
and the MH-reactions after sevoflurane were less fulminant compared
to the MH-reactions after halothane 3. In Japan, where sevoflurane
has been used since 1990, four patients have been described in whom
MH developed during sevoflurane anaesthesia 4-6. Sevoflurane may or
may not have been the cause of the MH-reactions. Otsuka et al.
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encountered a case of fulminant MH in a child with central core 
disease, which is closely related to MH 4. Ochiai et al. described two
patients with a MH-reaction but in one of these cases an other trig-
ger-agent (isoflurane) had been administered 5. Maeda et al.
described delayed recovery from muscle weakness in a patient with a
likely diagnosis of MH triggered by sevoflurane 6. In Europe, two
patients have been described in whom MH developed during sevoflu-
rane anaesthesia 7, 8. In both cases diagnosis of susceptibility to MH
was established using an in vitro contracture test (IVCT).
To prove that sevoflurane alone can trigger MH in humans, we
exposed muscle biopsy samples from MH susceptible patients to
sevoflurane in the IVCT. The caffeine and halothane IVCT is generally
accepted as the best standardized test we have available at the
moment for diagnosis of MH susceptibility 9-11.
To compare the potency of inducing a contracture, sevoflurane
concentrations in the testbath were measured.
Methods
Muscle fascicles were tested from three MH susceptible (MHS) patients,
one MH negative (MHN) patient, two negative tested (MHN) control
patients and one patient whose muscle had an abnormal contracture
response to halothane but normal response to caffeine and was there-
fore classified as MH equivocal (MHE) according to the protocol of the
European MH Group 9, 11. The muscle fascicles for this study were surplus
to diagnostic requirements or from control patients who gave written
informed consent; the study was approved by the local Ethics Committee.
Immediately after excision, the muscle specimen from the
quadriceps femoris muscle was placed in Krebs-Ringer solution (118.1
mmol/l NaCl; 3.4 mmol/l KCl; 2.5 mmol/l CaCl2; 1.2 mmol/l KH2PO4; 0.8
mmol/l MgSO4; 11.1 mmol/l glucose; 25.0 mmol/l NaHCO3; pH: 7.4) at
ambient laboratory temperature and bubbled with carbogen (5% CO2;
95% O2). Muscle fascicles (length 20-25 mm, weight 100-200 mg) were
dissected from a larger piece of muscle and placed in a 25 ml testbath,
filled with Krebs-Ringer solution at 37°C bubbled with carbogen 100
ml/min. After a 5-min rest, the muscles were stretched slowly to 150%
of the initial length and stimulated directly with a 1 ms square wave
single supramaximal stimulus at a frequency of 0.2 Hz (Grass S48
stimulator). The twitch responses were recorded on a Kipp & zn BD 100
recorder using a Schaevitz FTD-G-10 force transducer and measured at
least 10 mN before the administration of sevoflurane. After another
rest of 15 minutes during which stable baseline tensions were
achieved, sevoflurane was delivered incrementally at 1, 2, 3, 4, 5, 6, 7
and 8% through a calibrated vaporiser (Penlon™, Sigma Elite). Each
dose being maintained for 5 min.
The threshold value is the minimal concentration of sevoflurane
at which a sustained baseline contracture of 2 mN or greater occurs.
Sevoflurane concentrations in the carbogen were measured with
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an Ohmeda 5250 RGM analyser. Sevoflurane concentrations in the 
liquid phase were measured using a headspace gas chromatographic
technique (Chrompack, CP-9001, equipped with a flame ionisation
detector) 12. The injection port of this chromatograph was installed
with a glass liner (length: 8 cm; o.d. 6 mm; i.d. 3 mm). Column: 2 m
x 2 mm i.d. glass, packed with 10% SP 1200/1% H3PO4 on 80/100
Chromosorb W AW. The column and glass liner were stoppered with
glass wool. Column temperature: 100°C (isothermal), injection port
temperature: 200°C; detector temperature: 180°C. Carrier gas: 
N2 30 ml/min; H2 30 ml/min; air 250 ml/min. Injection (1 ml of
headspace gas) was performed in the empty liner, in one stroke.
For external standardization, we added to 4 septum closed glass vials
of 15 ml filled with 1 ml of Krebs-Ringer solution, respectively 0.25, 0.50,
1.0 and 2.0 ml of a standard gas mixture with a sevoflurane concen-
tration of 0.5 mmol/l. The mixtures were vortexed and equilibrated
for 2 min. Injection of 1 ml of the headspace gas resulted in a single
peak of sevoflurane with a retention time of 0.70 min. Plotting of the
peak area against the concentration resulted in a linear calibration
graph (figure 1). The testbath solutions were sampled using gas-tight
glass syringes. One millilitre of these testbath solutions was injected
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figure 1 Calibration graph: gas chromatographic peak area of sevoflurane after injection of 1 ml 
of headspace gas, sampled out of 4 septum closed glass vials of 15 ml, filled with 1 ml 
Krebs-Ringer solution with 0.25, 0.5, 1.0 and 2.0 ml standard gas (sevoflurane concentration
0.5 mmol/l), resulting in concentrations of respectively 0.125, 0.25, 0.5 and 1.0 mmol/l. 
The standard error of the x-coefficient (260 area units/(mmol/l)) is < 1%.
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into a septum closed 15 ml glass vial and treated in the same way as
described above for the calibration solutions. The concentrations of
the testbath solutions were derived from the calibration graph. By
using a fixed 1 ml fluid to 14 ml gas ratio in both measuring and 
standardization experiments, we did not have to take the Oswald
lambda into account, since it is eliminated from the formulas 12.
The equilibration characteristics in the bath were investigated by
measuring sevoflurane concentrations in the testbath as a function 
of duration of bubbling. Samples were taken after 30 s, 1, 1.5, 2, 2.5,
3, 4 and 5 min of bubbling with 2% sevoflurane in carbogen, 100
ml/min. The kinetics of sevoflurane concentrations in the bath were
evaluated on mean data by non-linear regression analysis, assuming
a one-exponential saturation process.
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1% 2% 3% 4% 5% 6% 7% 8%
MHS 1 1 6 8 10 11 10 11 12
MHS 2 0 1 3 4 6 8 8 7
MHS 3 0 0 1 2 3 4 4 3
MHE 1 1 1 2 2 3 3 4
MHN 0 0 0 0 0 0 1 0
Control 1 0 0 0 0 0 0 0 0
Control 2 0 0 0 0 0 0 0 0
table 2 Sevoflurane in vitro contracture test results. Contracture response in mN following 
cumulative administration of sevoflurane in skeletal muscle specimen (2 mN or greater
is interpreted as a positive contracture response).
Halothane Caffeine
threshold 0.44 mmol/l threshold 2.0 mmol/l
mmol/l (mN) mN mmol/l (mN) mN
MHS 1 0.11 (12) 24 0.5 (5) 28
MHS 2 0.11 (5) 26 0.5 (3) 16
MHS 3 0.22 (6) 13 1.0 (2) 12
Control 1 NR 0 32 (110) 0
Control 2 NR 0 4.0 (2) 0
MHE 0.44 (2) 2 3.0 (3) 1
MHN NR 0 32 (140) 0
tabel 1 In vitro contracture test results in skeletal muscle specimens of malignant hyperthermia 
susceptible (MHS), equivocal (MHE), non-susceptible (MHN) and control patients. Threshold:
the lowest concentrations of halothane and caffeine which produce a sustained increase of
at least 2 mN in baseline force from the lowest tension reached 9, 11. The contractures were at
0.44 mmol/l halothane and 2.0 mmol/l caffeine. NR = not reached.
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Statistical analysis were performed using exponential time fitting
for the equilibration time and linear regression with a logarithmic
scale, resulting in coefficients with standard errors.
Results
The halothane and caffeine threshold values, the contractures at
0.44 mmol/l halothane and at 2 mmol/l caffeine are given in table 1. 
The equilibration time for the 25 ml testbath, filled with 
Krebs-Ringer solution and bubbled with 2% sevoflurane in carbogen, is
3 min (figure 2). A linear correlation was obtained between the 
percentage-vaporiser concentrations and the resulting concentrations
of sevoflurane in the liquid phase (figure 3).
The results from the sevoflurane IVCT are given in table 2. In
patient MHS 1, a positive contracture response of ≥ 2 mN was reached
at 2% sevoflurane, corresponding to 0.20 mmol/l in the liquid phase.
In muscle tissue from patients MHS 2, MHS 3 and MHE, sevoflurane
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figure 2 Equilibration of sevoflurane in the liquid phase. Sevoflurane (2% vaporiser concentration) 
in carbogen (100 ml/min) bubbles through a 25 ml testbath. The testbath solutions were
sampled before and at 0.5, 1, 1.5, 2, 3, 4 and 5 minutes after the start of the sevoflurane
perfusion. The dotted dividing lines represent the range of the target values (0.20 mmol/l
± 10%). Data points indicate the means of two measurements. Equilibration time is 
3 minutes. After 5 minutes 1/e time is 2.41 min, meaning the target value (90%) is always
reached at 5 minutes.
proefschrift_q4  07-09-2004  09:37  Page 68
threshold values were reached at 4%, corresponding to 0.40 mmol/l.
No contractures developed after exposure to sevoflurane in muscle
tissue from MHN and control patients.
Discussion
Identification of patients suspected to be susceptible to MH may be
accomplished on the basis of clinical history that documents the signs
of hypermetabolism during or after anaesthesia 13. To date, the caf-
feine and halothane IVCT is generally accepted as the best standardized
test we have available for the diagnosis of MH susceptibility, at least
until a less invasive DNA based diagnosis of MH susceptibility is 
available 10, 11.
We found an equilibration time for 2% sevoflurane in the open
system testbath (25 ml) of 3 min. Equilibration time for halothane,
which bubbles with 2% in a 25 ml testbath, was 1.5 to 3 min during
calibration studies, comparable to other centres 14. This halothane 
target value of 2% in the gas phase should correspond to 0.44 mmol/l
± 10% in Krebs-Ringer solution, assuming a Krebs-Ringer/gas 
coefficient of 0.78 14, 15. Experimentally, it was determined that a
vaporisor concentration of 2% sevoflurane resulted in a liquid 
concentration of 0.20 mmol/l (figure 3).
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figure 3 The kinetics of sevoflurane in the liquid phase, sampled from the 25 ml testbath. 
Sevoflurane is delivered in carbogen 100 ml/min, incrementally at 0.5, 1, 2, 3, 4, 5, 
6, 7 and 8% vaporiser concentration for 5 minutes. Data points indicate the means of
3 measurements. Deviation of a linear relation is less than 5% (standard error of the 
x-coefficient (0,103) is 0,0151).
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The sevoflurane threshold values were 0.20 mmol/l to 0.40
mmol/l in the MHS group and 0.40 mmol/l in the MHE individual.
In the EMHG protocol, the halothane threshold for susceptibility is
0.44 mmol/l 9, 11.
In terms of alveolar concentrations, 2% halothane in carbogen 
is clinically equivalent to 3 MAC (Minimum Alveolar Concentration). 
The MAC of sevoflurane, in O2, in a 25-year-old person is 2.5% thus, 
3 MAC sevoflurane is around 7% in carbogen. According to this line 
of reasoning, the sevoflurane threshold for susceptibility should be
0.70 mmol/l, which makes our MHS and MHE patients susceptible and
the MHN patients and the controls non-susceptible in the sevoflurane
IVCT. We realize that the small sample size we employed makes this
comparison more clinically relevant than statistically significant.
Differences in the physico-chemical properties of inhalational
anaesthetics, with special regard to solubility and volatile potency
may be an explanation of the different concentrations at which 
contractures developed in vitro. Variations in the genetic substrate
responsible for MH may be another explanation. The different
responses in vitro may partially explain the variation in clinical 
signs and symptoms of MH. Variations in MH responses, with special
attention to uneventful previous exposure to potent inhalational
agents are well-known and particularly hazardous because they
are unpredictable 16, 17.
In summary, sevoflurane can trigger malignant hyperthermia and
MH susceptible patients, therefore, should never be exposed to it.
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The European Group protocol for investigation of malignant
hyperthermia susceptibility
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1 The biopsy should be performed on the quadriceps muscle (either vastus
medialis or vastus lateralis), using regional (avoiding local infiltration) or gen-
eral anaesthetic techniques.
2 The muscle samples can be dissected in vivo or removed as a block for dissec-
tion in the laboratory within 15 min.
3 The excised muscle should be placed immediately in precarboxygenated
Krebs-Ringer solution with a composition of:
NaCl 118.1 mmol/l KCl 3.4 mmol/l
MgSO4 0.8 mmol/l KH2PO4 1.2 mmol/l
Glucose 11.1 mmol/l NaHCO3 25.0 mmol/l
CaCl2 2.5 mmol/l pH 7.4
The ion concentration of the Krebs-Ringer solution should be as stated with 
a maximal deviation of ± 10%, and should be checked at least every month.
pH should be in the range 7.35-7.45 at 37°C.
4 The muscle should be transported to the laboratory in Krebs-Ringer solution
at ambient temperature. In the laboratory it should be kept at room 
temperature and carboxygenated.
5 The time from biopsy to completion of the tests should not exceed 5 h.
6 The tests should be performed at 37°C in a tissue bath perfused either 
intermittently or continuously with Krebs-Ringer solution and carboxygenated
continuously. At least four tests should be performed, each one a fresh specimen.
These include two static caffeine tests and two halothane tests. The halothane
test could consist of either one static and one dynamic test of two static tests.
Each laboratory should be consistent in the method employed. Separate tissue
baths should be used for different agents.
7 Muscle specimen dimensions. Muscle specimens suitable for in vitro investigation
should measure 15-25 mm in length between ties with a thickness of 2-3 mm.
For measurement of length, see 8 below. The weight of the specimens should
be 100-200 mg. The specimen are blotted and weighed after the test,
between sutures.
8 Determination of specimen length and predrug force. The static tests are 
performed at optimal length (l0) which is determined 5 min after suspension
of the specimen in the tissue bath by slowly stretching the muscle to force of
2 mN (0.2 g). The length between sutures is measured (initial length). Leave
the muscle for another 4 min at initial length, then commence electrical
stimulation (see 9 below) and stretch the muscle slowly to 150± 10% of initial
length. This new length is considered to be optimal length (l0) and is recorded.
Gassing of the Krebs-Ringer solution is stopped temporarily during measurement
of length. The muscle is left at optimal length (l0) to stabilise for at least 15 min
and until baseline force does not vary more than 2.0 mN (0.2 g) within a 10-min
period. Then drugs may be added. The baseline force immediately before
addition of drug is recorded as the predrug force.
9 Electrical stimulation. To demonstrate viability, the muscle specimen should be
electrically stimulated with a 1-2 ms supramaximal stimulus at a frequency of
0.2 Hz. Following suspension of the muscle in the tissue bath and obtainment
of initial length, current or voltage is slowly increased until twitch height
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does not increase any more (initial stimulus intensity). For the supramaximal
stimulation, the current or voltage is increased to 120% of initial stimulus
intensity.
10 The static cumulative caffeine test and measurement of the caffeine threshold.
The concentrations of caffeine (as free base, analytical grade) in the tissue
bath should be increased stepwise as follows: 0.5; 1.0; 1.5; 2.0; 3.0; 4.0; and
32 mmol/l. Each successive concentration of caffeine should be administered
as soon as the maximum contracture plateau induced by the previous concen-
tration of caffeine has been reached, or after exposure of the muscle to the
caffeine concentration for 3 min if no contracture occurs. The muscle is not
washed with fresh Krebs-Ringer solution between successive concentrations 
of caffeine. Caffeine should be added to the tissue bath either as a bolus by
injection, or with low-volume baths in the Krebs-Ringer perfusate. A rapid
change of caffeine concentration must be achieved. The result of this test will
be reported as the threshold concentration which is the lowest concentration
of caffeine which produces a sustained increase of at least 2 mN (0.2 g) in
baseline force from the lowest force reached. In addition, the maximum 
contracture achieved at 2 mmol/l caffeine should be reported. Please note
that the lowest force is not necessarily the same as the predrug force.
11 The static halothane test and measurement of static halothane threshold. 
The halothane threshold is obtained using the halothane concentrations 0.11;
0.22; 0.44 and 0.66 mmol/l as equivalent to 0.5; 1.0; 2.0 and 3.0 % v/v,
respectively. The specimen should be exposed to each halothane concentration
for 3 min. The measurement of halothane should also be reported. For deter-
mination of halothane concentration see 14 below. The flowrate of gas should
be set to maintain the correct halothane concentration in the tissue bath. The
gasflow into the tissue bath should be controlled using a low-flow rotameter
or similar device, situated close to the inlet port of the tissue bath. The time
to reach equilibration of the halothane concentration in the bath should be
determined in order to ensure that the muscle sample is exposed to the test
drug for the required period. The equilibration time will depend on bath 
volume, gas and perfusion flowrate and aerodynamics of the system.
12 The dynamic halothane test and measurement of dynamic halothane threshold.
This test is dependent on a motor. Initially, the muscle is stretched at a constant
rate of 4 mm/min to achieve a force of approximately 30 mN (3 g) and held at
this new length for 1 min. The stretching process is then reversed for 1.5 min.
The movement of the transducer from the end of the 1-min rest period to the
low force is measured accurately using a vernier scale. This measurement is
then used to achieve all subsequent length/tension curves, i.e. the muscle is
stretched and shortened 6 mm in each cycle. The muscle is allowed to rest for
3 min. The process is then repeated to obtain 3 control curves with 1 min rest
at high force and 3 min rest at low force. At the end of the descent of the
third control curve, the muscle is exposed to 0.11 mmol/l halothane (0.5 %)
for 3 min and the stretch process is repeated. The procedure is repeated for
0.22 and 0.44 mmol/l halothane (1 and 2 %).The force is measured at the end
of the 1-min rest after stretching and the dynamic halothane threshold is the
lowest concentration increasing force 2 mN (0.2 g). the maximal contracture 
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at 0.44 mmol/l is also recorded.
13 Diagnostic criteria
- MHS: A caffeine threshold (as defined earlier) at a caffeine concentration 
of 2.0 mmol/l or less, and a halothane threshold concentration at 0.44 
mmol/l or less.
- MHN: A caffeine threshold at a caffeine concentration of 3.0 mmol/l or 
more and a halothane threshold concentration above 0.44 mmol/l.
- MHE: All other results are deemed equivocal but designated MHEh if
reacting to halothane only or MHEc if reacting to caffeine only.
It is envisaged that most MHE patients will be regarded clinically as MH 
susceptible. MHE results must be considered to be under permanent
review pending the acquisition of further control and mutation data. 
MHE results should be treated separately in research studies.
14 Quality control
Viability in any specimen used should be demonstrated by twitches ≥ 10 mN 
(1 g) at the beginning of a test, or for the caffeine test a response to 32 mmol/l
≥ 50 mN (5 g) at the end.
The concentrations of halothane and caffeine in the tissue bath should be
checked at least every 3 months. The samples should be taken directly from
the tissue bath under the same dynamic conditions as when testing. Samples
for determination of halothane concentrations should be taken immediately
after the gas flow has been stopped to avoid sampling from the gas phase.
Halothane concentrations can be measured using GLC or HPLC and caffeine
using UV spectroscopy.
Halothane 0.44 mmol/l and caffeine 2 and 32 mmol/l should be checked. 
Accepted maximal deviation from the desired concentrations are ± 10 %.
Lambda halothane (air / Krebs-Ringer) is taken to be 0.72 at 37°C.
The vaporizer should be serviced and calibrated at yearly intervals. It is
recommended that halothane concentrations in the gas phase are monitored
close to the gas inlet port to the tissue bath.
Temperature of the tissue bath should be checked.
15 Control biopsies. All MH units are asked to investigate control muscle biopsies
according to this protocol. For control biopsies, the following groups of patients
are considered suitable: healthy volunteers, patients having amputations for
localized diseased (not systemic of vascular disease), patients with varicose
veins, brain-dead patients within the first 24 hours, patients with fractures
within the first 24 hours.
16 Optional tests. Tests with other drugs may be performed on an optional basis.
Results of optional tests are not used for diagnosis. However, to allow for
comparison of results between centres it is recommended that optional tests
are performed in a uniform way, agreed upon by the EMHG Board of Directors.
At present, protocols exist for tests with ryanodine and 4-chloro-m-cresol.
These protocols may be obtained from the group.
Protocol revision. The EMHG protocol for investigation of MH susceptibility is 
regularly revised, latest in May 1997, Nijmegen, The Netherlands
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Chapter 3
cultured human skeletal muscle cells
Halothane-induced calcium release in cultured 
human skeletal muscle cells from a family susceptible 
to malignant hyperthermia with an unidentified 
mutation in chromosome 19
Anesthesiology 2002; 97:272-274
Snoeck MMJ, Oosterhof A, Tangerman A, Veerkamp JH, van Engelen BG, Gielen MJM.
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Abstract
Studies on Ca2+ homeostasis in cultured human skeletal muscle cells,
obtained from fragments of biopsies of patients undergoing the in vitro
contracture test (IVCT) for malignant hyperthermia (MH) susceptibility,
have been performed. The purpose of the present study was to inves-
tigate the usefulness of cultured skeletal muscle cells, obtained by
percutaneous needle biopsies for determining MH susceptibility. 
Methods: Muscle samples from 6 MH susceptible (MHS) patients
and from 4 control individuals were used to culture myotubes. The
free cytosolic Ca2+ concentration ([Ca2+]i) of myotubes was determined
after exposure to halothane. [Ca2+]i on-line ratio measurement and
calibration were performed using Fura-2. To guarantee quality control,
all halothane concentrations were determined using a head space gas
chromatographic technique.
Results: There was no statistical difference in the mean resting
[Ca2+]i between cultured muscle cells from MHS or control individuals.
The dose-dependant Ca2+ response in cultured muscle cells of MHS
individuals is significantly different from that of control individuals
after exposure to halothane; in clinically used halothane concen-
trations. 
Conclusion: Cultured human muscle cells, obtained from needle
biopsies may well be applied in diagnostic tests for MH susceptibility.
Introduction
Malignant Hyperthermia (MH) is an autosomal dominant muscle disorder
characterized by a hypermetabolic crisis triggered by succinylcholine
and/or volatile halogenated anesthetic agents. The underlying cause
of MH is believed to be abnormal regulation of myoplasmic calcium
concentration in skeletal muscle 1, 2. A single mutation in the cDNA
sequence encoding the muscle ryanodine receptor (RYR1) was the first
to be considered as a candidate for causing MH in pigs 3. In human
MH the genetics is more complex; at least fifteen mutations in the
RYR1 gene have been reported to be potentially causative 4, 5. Beside
RYR1, secondary loci containing genes encoding proteins involved in
excitation-contraction coupling, such as the dihydropyridine receptor
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(DHPR) appeared to be causative 2.
A well defined diagnostic test for MH became available in 1971:
the in vitro caffeine and halothane contracture test (IVCT) 6, 7. The IVCT
is based on the hypersensitivity of muscle strips, obtained by biopsy,
to caffeine or halothane. Standardization in Europe and North
America led to two essentially similar protocols for the IVCT 8,9.
Cultured human skeletal muscle cells are often used to study muscle
pathology in which calcium homeostasis might be disturbed.
Excitation-contraction coupling of cultured muscle cells and their
excitability at stimulation is determined by their basal intracellular
calcium concentration ([Ca2+]i ) 10. We studied the effects of halothane
on the [Ca2+]i transients in human myotubes made up of cultured
skeletal muscle cells from MH susceptible patients and healthy controls.
Since such cells can be obtained by needle biopsy, our goal is to
determine if this would be a less invasive alternative of determining
MH susceptibility.
Materials and Methods
Patients
Muscle biopsies were obtained from four individuals without any
known muscular disorder, and from six MH susceptible (MHS) patients.
All patients gave written informed consent, formulated by the 
Committee on Medical Ethics of the University of Nijmegen. The MHS
patients were members of one single family in which a man in 1972
had died from MH. The MHS phenotypes were recognized by IVCT two
years before this study (table 1). Genetic analysis in this family showed
linkage to a candidate locus on chromosome 19 (lod score greater
than +3.0).
Human skeletal muscle cell cultures
Samples of the quadriceps femoris muscle were obtained by percu-
taneous needle biopsies (25-30 mg). Fragments were attached on 
the bottom of a 35-mm culture dish containing 1 ml proliferation
medium (Dulbecco’s modified Eagle medium (DMEM), 20% fetal calf
serum (FCS), 4.5 mg/ml glucose and 4 mM glutamine) and cultured in
a humidified CO2 incubator (5% CO2 ) at 37°C. The next day, this medi-
um was substituded by proliferation medium containing 4% Ultroser
G and 10% rat brain extract instead of FCS. After 7 to 10 days the
explants were removed, and the myoblasts were plated out on glass
coverslips (10x30 mm) in 35-mm dishes. Further proliferation took
place in 20% FCS containing medium until confluency was reached.
Differentiation to polynucleated myotubes was achieved 
in DMEM containing 10% horse serum for 7 days.
For cryopreservation about 106 myoblasts /ml DMEM containing
20% FCS and 10% dimethyl sulfoxide were stored in liquid nitrogen.
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[Ca2+]i on-line ratio measurement and calibration
The free cytosolic Ca2+ concentration ([Ca2+]i) was determined in
skeletal muscle cells using Fura-2 11. Myotubes were loaded with 5 µM
Fura-2/acetoxymethyl ester (Fura-2/AM) and 10 µM Pluronic acid for 90
min at 37°C in physiological salt solution (PSS: containing 10 mM
HEPES, 125 mM NaCl, 10 mM NaHCO3, 1 mM NaH2PO4, 5 mM KCl, 2 mM
MgSO4, 1.8 mM CaCl2, and 10 mM glucose, pH 7.4). On-line ratio meas-
urement were recorded with a Shimadzu RF-5301 spectrofluoropho-
tometer. Fura-2 fluorescence was measured at an emission wavelength
of 492 nm (bandwidth, 5 nm) and alternating excitation wavelengths of
340 and 380 nm (bandwidth, 3 nm). During the measurements the
cells in the cuvette were superfused with PSS (4.0 ml/min; 37°C) 
without or with different concentrations of halothane (0.11, 0.22, 0.44,
1.0, 2.0, 4.0, 8.0, 12.0 mM). Halothane was solved in dimethyl sulfox-
ide (DMSO) and added to PSS in airtight dark bottles. All fluorescence
signals were corrected for autofluorescence.
The 340/380 ratios (Fura-2) were calibrated using PSS containing 4 µM
ionomycin and 10 mM Ca2+ (pH 7.7; Rmax) or 4 µM ionomycin and 20
mM EGTA without external Ca2+ (pH 8.5; Rmin). [Ca2+]i was calculated
using the equation:
[Ca2+]i =Kd x ß x {(R-Rmin) / (Rmax-R)} Kd of Fura-2 is 224 nM 12
Assay of halothane concentration
Halothane concentrations in PSS were measured using a head space
gas chromatographic technique (Chrompack, CP-9001, equipped with
a flame ionisation detector) 13. 
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Halothane Caffeine
Patient(s) Threshold Contracture (mN) Threshold Contracture (mN)
(mM) at 0.44 mM (mM) at 2 mM
MHS1 0.22 8 1 10.5
MHS2 0.11 15 2 4
MHS3 0.22 12 1 7.5
MHS4 0.22 13 1 11
MHS5 0.44 4 0.5 21
MHS6 0.11 20 0.5 14
Controls - 0.2 32 0.1
table 1 IVCT results of muscle biopsies from six MHS individuals and averages for control individuals
(n=4). MHS: a caffeine threshold concentration at 2.0 mM or less, and a halothane threshold
concentration at 0.44 mM (2.0% v/v) or less; the threshold concentration is the lowest
concentration which produces a sustained increase of at least 2 mN (0.2 g) in baseline force8.
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Materials
Dulbecco’s modified Eagle medium (DMEM) and Ultroser G were from
Gibco BRL Life Technologies, Paisly, UK; fetal calf serum (FCS) and horse
serum from Flow Laboratories, Irvine, UK. Brain extract was prepared
from brains of 10 day-old Wistar albino rats as a 10% (w/v)
homogenate. Fura-2/acetoxymethyl ester (Fura-2/AM), ionomycine and
pluronic acid were purchased from Molecular Probes, Eugene, OR, USA.
Halothane was from Tempus b.v., Oegstgeest, The Netherlands.
Statistical analysis
Data are represents as mean (SD). Statistical analysis is performed using
the unpaired Students t-test. Significance was set at p<0.05. Curve fit-
tings were obtained by linear regression analysis. Individual area under
the curves (AUC) were determined from the curves by interpolation.
Results
Halothane concentrations in PSS were measured in the cuvette on
completion of the calcium measurements. We found a substantial 
difference between the intended concentrations and the measured
concentrations (intended→measured concentrations respectively:
0.11→0.095 (0.012) mM, 0.22→0.187 (0.029) mM, 0.44→0.33 (0.039)
mM, 1.0→0.69 (0.16) mM, 2.0→1.4 (0.20) mM, 4.0→2.75 (0.42) mM,
8.0→5.2 (0.99) mM, 12.0→7.5 (1.3) mM).
The 340/380 ratios of the Fura-2 calibration resulted in a 
Rmax of 11.88 (1.03) and Rmin of 1.59 (0.15); mean (SD) of eight experi-
ments. The constant ß, i.e. the ratio of the fluorescence emission of
the free dye and the Ca2+-saturated dye measured at 380 nm, is 3.09
(0.33) n= 7. We did not find a statistical difference between the mean 
resting [Ca2+]i in cultured muscle cells of MHS or control individuals,
which were respectively 65 (20) nM; (n= 72) and 58 (17) nM; (n=50).
Halothane produced a dose-dependent increase of [Ca2+]i (figure 1).
In the MHS group the Ca2+ response is observed in the clinically used
halothane concentrations (<1 mM). The Ca2+ response in cultured 
muscle cells of MHS individuals is significantly different from that of
control individuals and there is no overlap beyond 0.44 mM
halothane (equivalent to 2% v/v).
Discussion
Cultured human skeletal muscle cells have been very useful for 
studying ion homeostasis in relation to MH 14-17. Interpretation of the
results is complicated by the existence of incomplete maturation and
differences related to the heterogeneous population of cells at the
myotube stage. By analyzing the fluorescence signal composed of the
whole monolayer of myoblasts /myotubes on glass coverslips we were
able to compare the common behavior of thousands of cells instead
of a small selection of cells which was done in previous studies with
comparable aims 14,15,17. This could explain why we could discriminate
MHS from control muscle tissue using halothane in clinically used
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concentrations, whereas the other investigators needed much higher
halothane concentrations 15, 17. Further standardization of cell culturing
could improve reproducibility of test results even more. In the IVCT a
vaporizer is used to add halothane to carboxygen to solve halothane
in Krebs-Ringer solution 8. To reach supraclinical halothane concen-
trations, halothane was solved in DMSO before it was added 
to the physical salt solution. This procedure requires assay of
halothane concentration in the test bath at completion of each
experiment because the variations are common.
In this study we confirm that there is no difference in the resting 
intracellular calcium level between cultured muscle cells from MHS
and control individuals 2, 14, 15. 
A test based on cultured muscle cells obtained by a needle biopsy
is less invasive and is easily reproducible. The time between biopsy
and performance of the test is not critical because cell cultures can be
expanded, frozen and thawed. In contrast IVCT requires large muscle
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figure 1 Halothane-induced, dose-dependent increase of [Ca2+]i in cultured skeletal muscle cells from
6 MHS individuals (n = 42: solid dots and line) and 4 control individuals (n = 32: open dots
and dotted line). Discrimination between MHS and control is 100% beyond 0.5 mM
halothane (p < 0.05). Inset: [Ca2+]i response at clinically used halothane concentrations
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samples (surgically collected) and must be performed within 5 hours 8.
In conclusion: cultured human muscle cells obtained from needle
biopsies may well be applied in diagnostic tests for MH susceptibility.
More studies comparing data from the IVCT and cultured cells have to
be undertaken to determine sensitivity (and specificity).
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Chapter 4
procedure for the diagnosis
of MH susceptibility in Europe
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Abstract
The European Malignant Hyperthermia Group (EMHG) was formed in
1983 and now comprises 22 MH centres in 13 countries. However
although laboratory protocols have been critically evaluated, little has
been done to evaluate inter-centre standards for the clinical aspects
of MH. The purpose of this study was to see how MH centres deal with
the referral of patients and how this is reflected in workload and
funding. 
Methods: 4 MH centres (Belgium, The Netherlands, Switzerland
and UK) were asked to complete a questionnaire about their last
25 consecutive consultations and their overall workload for the past
5 years.
Results: All 100 questionnaires were sent back. The main reason
(81%) for consultation was a request for diagnosing MH susceptibility;
resulting in screening by the in vitro contracture test in 60 cases. The
variability in the number of tests performed during 1997-2001, put in
perspective of the catchment area of the centre, is high between 
centres but constant within centres. 
Conclusion: The number of tests performed appeared to be related
to the way a centre is funded. This study helped to gain an insight
into the need for further standardisation and quality assurance for
the diagnosis of MH.
Introduction
Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic
disease occurring during anaesthesia in which potent inhalational
anaesthetics and/or succinylcholine are used. It is inherited as an
autosomal dominant characteristic.
We studied the diagnostic procedures in 4 MH investigation units.
The purpose of this study was to see how MH centres deal with the
referral of patients and how this is reflected in workload and funding.
A well defined diagnostic in vitro test became available in 1970 1, 2. The
in vitro contracture test (IVCT) is based on the hypersensitivity of
viable muscle samples from “MH susceptible individuals”, obtained 
by biopsy, to caffeine and halothane. At present, the IVCT, performed
according to the European MH Group (EMHG) protocol, is generally
accepted as the “gold standard” test for the diagnosis of MH suscepti-
bility 3. Molecular genetic studies brought a DNA-based diagnosis of
MH susceptibility within reach. However, because MH displays a high
level of heterogeneity, MH susceptibility should only be diagnosed on
the basis of genetic studies according to guidelines published by the
EMHG 4.
The EMHG was formed in 1983 and now comprises 22 MH centres
in 13 countries. One purpose of the EMHG is to ensure comparable
standards both in the diagnostic testing for MH and in how patients
and their families are dealt with. Laboratory technology has been
subjected to critical evaluation 5, but little has been done to evaluate
90
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inter-centre standards for the clinical aspects of MH dealing with the
clinical referrals and the criteria for refusing or accepting a proband
for testing. 
Methods
Representatives of the MH investigation units in Belgium, The
Netherlands, Switzerland and the United Kingdom were asked to
complete a two-part questionnaire. The first part contained general
questions, including questions about funding and the total number
of tests performed and their outcome during the last 5 years. In the
second part the centres were asked to describe their last 25 consulta-
tions and to describe the basis of their decision to select patients
requiring further investigation. This included questions about the type
of clinical referral, patient information, outcome of the consultation
and the diagnostic results when these were performed.
Results
The MH investigation units in Belgium, The Netherlands, Switzerland
and the UK have been members of the EMHG since 1985, 1983, 1987
and 1983 respectively. The catchment areas of the four national MH
investigation units in Antwerp (B), Nijmegen (NL), Basel (CH) and 
Leeds (UK) encompass 11, 16, 7, and 58 million inhabitants 
respectively (table 1). National health care system in the UK covers all
costs in Leeds, based on 230 biopsies per year. Basel has been reim-
bursed for all costs since July 2000 (before that Swiss health care sys-
tem covered approximately 50% of IVCT costs). IVCT costs in Belgium
and The Netherlands have to be paid from (shrinking) institutional 
budgets. The number of tests performed in latter 2 countries, is just
over 1 test per 1.000.000 inhabitants per year while this amount is at
least 5 times higher in both countries where all IVCT costs are covered
by the healthcare system. Based on this finding it appears that ade-
quate funding influences the decision whether IVCT will be performed
to a major extent.
The majority of consultations were by telephone (85%), either by
the patients themselves or more usually by anaesthetists (table 1). In
81 of 100 cases the reason for the consultation was a request for dia-
gnosing MH susceptibility. 29 cases concerned patients that have had
an adverse reaction to anaesthesia. The remaining 52 cases concerned
relatives of a known MH susceptible family. In total, 65 individuals
were offered further investigation, 60 by IVCT and 5 by a DNA test
according to the guidelines 4. Because of incomplete clinical informa-
tion, 9 referrals were put on a waiting list, in expectation of further
details. 7 cases were deemed not to require further investigation on
the basis of clinical information alone i.e. there was a clear reason for
the clinical reaction other than MH.
proefschrift_q4  07-09-2004  09:37  Page 91
The 4 MH investigation units select probands for screening in a
similar but individual way based on experience (figure 1). All 4 centres
except the one from the UK use the Clinical Grading Scale (GSC) as a
basis for selection. Although the GCS is objective it can be hampered
by incomplete clinical information, which is a common situation 6. 
For this reason the Leeds centre uses clinical categories developed
from a review of 402 probands that gives an incidence rate or likeli-
hood of MH for each category of clinical presentation but it is a sub-
jective method 7.
Discussion
MH centres have been offering advice about MH and providing a 
diagnostic screening service for patients and their families. This has
led to thousands of patients being assigned to be MH-susceptible
(MHS/E), or MH-normal (MHN) with regard to future anaesthesia. It
might be argued that the major role of an MH investigation unit was 
to exclude the clinical diagnosis of MH rather than confirm it, thus
preventing patients and their whole families from becoming falsely
labelled as MH susceptible.
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UK B CH NL Total
NOT
1997 257 21 30 14 322
1998 241 14 36 15 306
1999 256 15 43 10 324
2000 198 15 37 14 264
2001 202 16 73 18 309
AOC 58 11 7 16 92
NHS funding + - + -
CONSULTATIONS
Referred by
Anaesthetist 9 4 6 9 28
GP 4 5 6 4 19
Other clinician 2 5 1 4 12
Self referral 4 11 12 7 34
Centre advise 6 - - 1 7
Reason for consultation
General info about MH 8 2 - 4 14
Anaesthesia advise 3 - - 2 5
Request for diagnosing 14 23 25 19 81
table 1 Data collected by a questionnaire; reply from 4 European MH investigation units. NOT:
Number of in vitro contracture tests (IVCT) performed during 1997-2001; area of catchment
(AOC) in million inhabitants; the national healthcare system (NHS) is funding the IVCT 
separately. Data collected from 100 consultations.
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In recent years the “incidence” of clinical MH has tended to
decrease because of increased use of regional anaesthesia and total
intravenous anaesthesia, both “MH safe” techniques together with a
decrease in the use of succinylcholine. As the combination of
succinylcholine and inhalational anaesthetic agents produces a more
profound MH reaction, the signs of MH are now often less pronounced
and can occur insidiously. Mild forms of MH could therefore be
missed, although conversely the increased index of suspicion of MH by
anaesthetists has lead to an increase in referrals of mild, non-specific
reactions. However fulminant classical MH reactions do still occur. 
A decrease in referrals maybe be expected, but for the time being the
referral rate varies considerably from year to year, so it is not yet clear
if this is a true trend (unpublished information from MH experts 
during the Xth International Workshop on MH, June 2003, Brunnen,
Switzerland).
The present study provided an insight into the need for further
standardisation and quality assurance for the diagnosis of MH. The
number of referrals was to low to demonstrate inter-centre difference
between IVCT indication criteria and IVCT results. Meanwhile a
European quality assurance project financed by the EMHG has been
started, based on an independent on-site visiting programme to all
22 European MH investigation units. Quality assurance and greater
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Known causative MH 
mutation
Calculated MH 
susceptibility risk < 25%
Investigation for causative MH mutation
Susceptible to MH
DNA test for MH mutation
Calculated MH 
susceptibility risk
 ≥ 25% or(*)
Intervening relatives, 
with risk ≥ 25%
No further investigation
Member from an MH family
Meet presetted criteria
(e.g. CGS>D3)
Fall short of the clinical 
criteria (e.g. CGS<D4)
Causative MH mutation 
not known
Patient referred for MH screening
Proband 
IVCT
MHSMHN MHE
Present
Absent
Figure 1 Suggested route for counselling.
IVCT = in vitro contracture test 3; MHS = malignant hyperthermia susceptible; 
MHN = malignant hyperthermia normal; MHE = malignant hyperthermia equivocal. (*) = when
calculated MH susceptibility risk <25% but intervening relatives either deceased or refused
investigation. CGS = clinical grading scale to predict MH susceptibility 6.
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standardisation within the EMHG will improve confidence in the diag-
nostic screening for MH susceptibility. It will encourage communica-
tion and collaboration within the MH research infrastructure. Finally it
will improve the safety of MH susceptible patients and their families,
who need to undergo anaesthesia.
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Abstract
Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic
disease triggered by several anaesthetic agents. The in vitro muscle
contracture test (IVCT) is the standard test to establish an individual's
risk of susceptibility to MH. Clinical practitioners and geneticists of the
European MH Group have agreed the present guidelines for the detec-
tion of MH susceptibility using molecular genetic techniques and/or
IVCT to predict the risk of MH.
Introduction
Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic
disease triggered by commonly used potent inhalation anaesthetics
and/or succinylcholine. The in vitro muscle contracture test (IVCT) is
the standard test to establish an individual's risk of susceptibility to
MH 1. The European MH Group has developed a standardized protocol
for the IVCT and has initiated and fostered international collaborative
molecular genetic studies to investigate the molecular basis of MH.
Data from these studies demonstrate that MH displays a high level 
of locus heterogeneity. Thus, it is not feasible to diagnose MH 
susceptibility, and, more specifically, to exclude MH risk, on the basis
of a simple genetic test alone. However, it is of utmost importance to
avoid false MH-negative (MHN) diagnoses because of the potential risk
of MH during general anaesthesia for these patients and their offspring.
These general obstacles notwithstanding, there may be specific situations
where genetic data provide additional diagnostic information or 
contribute information independent of IVCT. It is the purpose of
this document to outline recommended procedures for the potential
diagnostic use of such genetic findings depending on the different
clinical situations that may arise. 
Referrals
The usual route of entry for individuals into MH investigations 
follows a suspected MH crisis and referral of the patient to an MH
Investigation Unit, where diagnostic procedures and genetic counsel-
ling should be performed according to figure 1.
In vitro muscle contracture test (IVCT)
An IVCT is performed on the patient or, if the patient is too young 
or has not survived the anaesthetic event, his or her parents. If MH
susceptibility status is confirmed by IVCT, then there is a clinical
responsibility to offer the IVCT to the relatives of the index case,
assuming autosomal dominant inheritance and starting with 
first-degree relatives.
Genetic investigations
Mutation analysis
At this stage molecular genetic testing for causative mutations in the
96
proefschrift_q4  07-09-2004  09:37  Page 96
ryanodine receptor gene (RYR1) of the index case could lead to quicker
results for the rest of the kinship. An up-to-date list of mutations
that have been shown to directly alter RYR1 caffeine or halothane
sensitivity is shown in table 1 and table 2. 
Genetic analysis should be performed in, or only after consultation
with an MH Investigation Unit. Once a causative mutation has been
detected in the proband or index patient, it can be used to test relatives
who have not yet been tested by IVCT. Mutation carriers should conse-
quently be regarded as susceptible to MH. However, family members
who do not carry the mutation observed in the pedigree should 
still undergo IVCT investigation. The reason for such caution is the
observation in several pedigrees investigated by members of the
European MH Group of discordance between genetic and IVCT results,
implicating a second MH susceptibility gene segregating in the
kinship 2, 3.
Segregation analysis
Once the MH status of the extended pedigree (e.g. 10 informative
meioses) has been determined by the IVCT, it may be possible to
undertake genetic segregation analysis with markers close to the
known MH susceptibility loci. An up-to-date list of recommended
markers and details of genetic modelling compiled by the European
Malignant Hyperthermia Group, Genetics Section, is available on the
internet (http://www.emhg.org).
Rarely a single pedigree may be sufficiently large to establish
linkage to a candidate locus with a high probability (lod score >3.0).
In such a situation the question arises as to whether or not haplotype
analysis can be used to assign MH status. Under these circumstances
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- Probands
- Relatives of suspected MH patients
- Members from MH families with no 
   causative mutations
Patient referred for MH screening
DNA test for MH mutation
MHSMHN
PositiveNegative
Family history with a 
causative MH mutation
IVCT PresentAbsent
figure 1 Suggested route for MH susceptibility testing. IVCT = in vitro muscle contracture test; 
MHN = malignant hyperthermia negative; MHS = malignant hyperthermia susceptible.
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individuals carrying the high-risk haplotype should be regarded as
susceptible to MH even without confirmation by a positive IVCT. The
converse is not true, that is, identification of the low risk haplotype
does not equate with MHN status and such individuals should have
IVCT determination of their MH status.
In families where linkage to a candidate gene, RYR1 or another
locus, is suggested but not firmly established (i.e. lod score <3.0)
haplotype analysis for predictive testing is not appropriate due to the
high level of locus heterogeneity in MH. In such families, however, it
is desirable to search for unknown mutations in the suggested candi-
date gene for research purposes.
Failure to reach a lod score of +3.0 in a single family due to the
occurrence of a single individual in whom there is recombination
between the haplotype and IVCT-determined MH status will require
closer scrutiny and possible reassessment of the genetic and bioassay
results to attempt to resolve the basis of the discordance. For predic-
tive diagnosis in such families the more conservative estimation, i.e.
the higher risk outcome (either the MH susceptibility test result from
the IVCT or the high-risk haplotype) should be the basis for the clinical
decision.
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Exon Mutation position RYR1 amino Reference
codon change acid change
2 103 T>G Cys35→Arg 4
6 487 C>T Arg163→Cys 5
9 742 G>A Gly248→Arg 6
11 1021 G>A Gly341→Arg 7
12 1209 C>G Ile403→Met 5
14 1565 A>C Tyr522→Ser 8
15 1654 C>T Arg552→Trp 9
17 1840 C>T Arg614→Cys 10
17 1841 G>T Arg614→Leu 11
39 6487 C>T Arg2163→Cys 12
39 6488 G>C Arg2163→His 12
45 7300 G>A Gly2434→Arg 13-15
45 7304 G>A Arg2435→His 16
46 7372 C>T Arg2458→Cys 17
46 7373 G>A Arg2458→His 17
table 1 List of RYR1 mutations potentially causative for MH susceptibility (MHS) and central core disease
(CCD). Residue numbering within the RYR1 nucleotide and amino acid sequence corresponds
to the human RYR1 sequence according to Zorzato and colleagues 18 (accession number
J05200.1), updated according to Zhang and colleagues 16 and Phillips and colleagues 19.
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24 Lynch PJ, Tong J, Lehane M, Mallet A, Giblin L, Heffron JJ, Vaughan P, Zafra G,
MacLennan DH, McCarthy TV. A mutation in the transmembrane/luminal domain of the
ryanodine receptor is associated with abnormal Ca2+ release channel function and
severe central core disease. Proc Natl Acad Sci U S A 1999; 96: 4164-4169.
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Clinical practitioners and geneticists of the European MH Group (EMHG) have
agreed on the guidelines for detection of MH susceptibility using molecular genetic
techniques and/or IVCT to predict the risk of MH. The original (2001) guidelines
contained 15 RYR1 mutations for genetic testing. Once one of these causative
mutations has been detected in the proband, who’s MH susceptibility status 
is confirmed by IVCT, it can be used to test relatives.
On its 22nd Annual Meeting in Brunnen, Switzerland, the EMHG has discussed 
criteria which any genetic mutation should fulfil prior to its use in predictive
genetic testing. The following criteria concerning genetic and functional charac-
terization have been adopted.
Genetic characterization:
- A full description at the DNA and protein level, considering aspects of evolu-
tionary conservation and change in charge, polarity or structure introduced by
the amino acid replacement.
- Co-segregation of the mutation with the disease in at least 2 pedigrees.
- Absence of the sequence change from 100 control samples for exclusion of
polymorphisms.
Functional characterization:
- Recombinant in vitro expression on a defined genetic background.
1 The standard system uses the expression of a rabbit RYR1 cDNA construct
(with appropriate mutations) in HEK293 cells. Calcium release is measured 
fluorimetrically in response to trigger agents. Although this is a non-muscle
cell type, the advantage of the system is the defined cDNA and the 
standardised genetic background of the recipient cell line. This allows 
for direct comparison between mutations and eliminates the potential
influence of mutations in other genes which could modify RYR1 function
in cells taken from patients.
2 Alternatively, myotubes of the dyspedic mouse (RYR1-knock out) have
been used as recipients for the expression of cDNA constructs. cDNA
construct and genetic background are well defined and standardised. 
The genetic expression profile of myotubes may be closer to mature 
muscle. For this reason, results may not be directly comparable to the
HEK system.
- Assays of RYR1 function in ex vivo tissues. Calcium measurements and ligand
binding studies have been performed on tissues from MHS patients with 
characterised RYR1 mutations:
1 in myotubes
2 in microsomal SR preparations from muscle biopsies
3 in lymphoblasts
Read-out parameters were Ca2+ flux and resting [Ca2+] or 3H-ryanodine 
binding to SR-RYR1 preparations. Myotubes and lymphoblasts were derived
from individual patients and, therefore, the potential influence of other
individual genetic factors cannot be excluded. For the SR preparations, 
muscle biopsies of several patients were pooled thus eliminating individual
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variation. In order to avoid the interference of genetic factors other than RYR1,
it is recommended that all assays which are based on cells taken from
patients should be performed on samples from at least two independent
patients with the same mutation.
Please note: candidate mutations are eligible for the list of “Mutations for genetic
testing” only if results of their genetic and functional characterisation have been
published in the scientific literature. An up-to-date list of mutations, recommended
markers and details of genetic modelling is available on the internet:
http://www.emhg.org
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Exon Nucleotide Protein Phenotype Assay system(s)
39 6502 G>A V2168M MH Ca2+ release in mutant lymphoblastoid cells and
myotubes from several mutation carriers
40 6617 C>T T2206M MH Ca2+ release in mutant myotubes cultured from 
several mutation carriers
44 7048 G>A A2350T MH Mutant rabbit RYR1 expressed in HEK-293cells. 
100 14387 A>G Y4796C MH? / CCD Mutant rabbit RYR1 expressed in HEK-293cells. 
& nemaline 
rods
101 14512 C>G L4838V MH Mutant rabbit RYR1 expressed in CHO cells.
101 14582 G>A R4861H CCD /MH? Measured changes in intracellular [Ca2+] of mutant
lymphoblastoid cells
102 14693 T>C I4898T MH / CCD Mutant rabbit RYR1 expressed in HEK-293 cells and in
dyspedic myotubes
table 1 As of December 2003, 7 novel RYR1 mutations have been recommended for use of predictive
genetic testing within pedigrees, as these 7 causative mutations met the EMHG criteria.
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Chapter 5
screening for MH susceptibility
Investigation of a family following fulminant 
malignant hyperthermia
Journal of Clinical Neuromuscular Disease 2004; 5: 122-128
Snoeck M, Sengers R, Iles D, ter Laak H, Robinson R, Padberg G.
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Abstract
Malignant hyperthermia (MH) is a pharmacogenetic neuromuscular
disorder triggered by inhalational anaesthetics or succinylcholine.
We studied in detail 24 relatives of a patient who died after suffering
MH. All steps of the screening procedure, follow developments in
testing for the diagnosis of MH susceptibility from 1984 until 2002.
Patients and methods: The screening procedure contained a 
general assessment and a clinical examination; CK measurement;
genomic DNA isolation for linkage analysis and mutation screening;
muscle samples were tested according to the in vitro contracture test
protocol (IVCT) and examined histologically; cultured skeletal muscle
cells were used to examine the effect of halothane on the intracellular
calcium concentration.
Results: No correlation was found between IVCT results, serum CK
or abnormal findings following histological examination, though CK
elevation and the observation of cores seemed indicative for MH 
susceptibility in this family. Linkage analysis implicated RYR1 on 
chromosome 19q13.1 as the disease susceptibility locus in the family.
The calcium response was found to be significantly different.
Conclusion: Following three decades of screening for MH, the gold
standard for diagnosis remains the IVCT for detection of susceptibility
to MH.
Introduction
A 34 years old man died in intensive care on August 21th 1973 after
suffering a fulminant malignant hyperthermia crisis during general
anaesthesia in the ear, nose and throat department for correction of
a deviated nasal septum the previous day. The patient developed
hyperkalaemia that led to recurrent ventricular fibrillation and
ischemia. As a result, the patient suffered multiple organ failure that
later proved fatal.
During case reconstruction, ten years later, the attendant anaes-
thetist reported reduced mouth opening and increased jaw tone
which made intubation of the trachea difficult. The patient was
anaesthetised with thiopental, meperidine, succinylcholine, nitrous
107
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oxide, oxygen and halothane. Other early clinical signs were tachycar-
dia, cyanosis and low blood pressure. In spite of supplementary clini-
cal information, we concluded that we had been presented with a
fulminant MH crisis. As a result, we felt it necessary to test the close
relations of the deceased proband for susceptibility to MH.
Denborough and co-workers were the first to recognise the
hereditary nature of MH susceptibility 1. By their observations on an
Australian family in which several members had died during anaes-
thesia, they proposed that the pattern of predisposition to MH was
compatible with an autosomal dominant mode of inheritance.
At present the in vitro contracture test (IVCT) is generally accepted
worldwide as the most reliable test for diagnosis. Based on two tests
involving the exposure of living muscle samples to caffeine, devel-
oped by Kalow in 1970, and halothane, developed by Ellis in 1971, the
IVCT is used to assess susceptibility to MH2, 3. Standardisation of the
IVCT in Europe and North America has led to two essentially similar
protocols for the caffeine and halothane IVCT 4, 5.
In this paper we describe a pedigree of a patient with MH. All
steps of the MH-screening procedure from 1987 until 2002 follow the
developments in testing for the diagnosis of MH susceptibility.
Patients and Methods
Patients
24 first and second degree relatives of the proband were screened for
MH susceptibility. Family screening was initially offered to first-degree
relatives with 50% chance of susceptibility, assuming autosomal
dominant inheritance. In this family this included 10 siblings, 2 sons
and the daughter of the proband; the parents and sister of the
proband are deceased and were not tested (pedigree in figure 1).
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I V VI VII VIII XIIXIX
2 1 1 2 3 4 5 1 5 1 2 3 2 1 24
MH Indexcase
Deceased
Not tested
MH Susceptible
MH Normal
MH Equivocal
figure 1 Pedigree.
proefschrift_q4  07-09-2004  09:37  Page 108
The screening procedure consisted of a general assessment, history and
clinical examination of each patient by a specialist in neuromuscular
diseases. Blood samples were taken for CK measurement and genetic
investigations. A muscle biopsy was performed on the quadriceps
muscle (either vastus medialis or vastus lateralis), using a regional
anaesthetic technique (a femoral 3-in-1 nerve block). Muscle tissue
was removed as a block for dissection in the laboratory; parts of the
biopsy were reserved for histological examination.
The appropriate informed consent was obtained from all patients.
In vitro contracture test
The IVCT was performed according to the guidelines of the protocol of
the European MH Group 4. Briefly, fresh muscle bundles were placed in
tissue baths, filled with carboxygenated Krebs-Ringer solution and
stretched for optimal preload. After equilibration for a stable resting
tension, caffeine or halothane were added cumulatively to the tissue
bath. Two caffeine tests and two halothane tests were performed in
separate baths. For each test, fresh muscle bundles were used and
during testing the muscle bundles were stimulated to indicate the
viability.
The results were regarded as positive if a sustained increase in
resting tension (contracture) of 2 mN or greater was developed with 2
mM caffeine or less and with 0.44 mM halothane or less. In this case,
the patient was classified as MH-susceptible (MHS). When both tests
were negative, the patient was classified as MH-normal (MHN). All
other results were designated MHE: equivocal. Both MHS and MHE
patients are regarded as clinically susceptible to MH.
Histological examination
Histological examination is a part of the muscle biopsy screening pro-
cedure to exclude the existence of an underlying muscle disease that
could account for any problems encountered during anaesthesia. The
usual colourations and histoenzymatic reactions carried out routinely
for diagnosis were performed on selected, oriented and rapidly frozen
muscle specimens.
In order to compare muscle biopsy abnormalities with MH-status,
each abnormal finding was scored (table 1). The MA-score (morpho-
logical abnormality score) of the biopsy is the number obtained by
summation of scores belonging to the defined abnormal findings in
the biopsy.
Statistical analysis is performed using the unpaired Student t test;
significance was set at P<0.05.
Genetic investigation
MH susceptibility in the majority of white families is linked to the
gene encoding the skeletal muscle ryanodine receptor (RYR1), the cal-
cium release channel of the sarcoplasmic reticulum, on chromosome
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19q13.2 6. Genomic DNA was isolated from EDTA whole blood according
to the method described by Miller 7. For linkage analysis, microsatel-
lite markers D19S75, D19S191, D19S414, D19S220 and D19S412 were used
to generate haplotypes. Using the LINKAGE based package, MSIM, the
average and maximum two-point lod scores were computed.
Screening for all known RYR1 mutations in the hot-spot regions 
(106 to 2024 bp, 6188 to 7462 bp and 14313 to 15204 bp), was under-
taken by direct sequencing of polymerase chain reaction (PCR) prod-
ucts as outlined elsewhere 8. 
Skeletal muscle cell cultures
Muscle samples from 6 known MHS family members were compared 
to 4 unrelated control patients without any known neuromuscular
disease. Samples of the quadriceps femoris muscle were obtained by
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Morphological abnormality incidence score
Internal nuclei (IN) 4-5% 1
6-10% 2
11-20% 3
21-40% 4
41-80% 5
Type I fibres <20% or >65% 1
Type IIC fibres >5% 1
Ring fibres 1 or 2 1
Basophilic fibres 1 or 2 1
Necrotic fibres or myophagia 1 or 2 1
Tubular aggregates in fibres 1 or 2 1
Cores 1 or 2 1
Fibre splitting 1 or 2 1
AcP signalled changes 1 or 2 1
Granular fibres 1 or 2 1
Ragged red fibres 1 or 2 1
Fibres containing large fat vacuoles 1 or 2 1
Lobulated fibres 1 or 2 1
Cellular infiltration small 1
Angular fibres 1 or 2 1
Atrophic fibres with only nuclei 1 or 2 1
Atrophic fibres 1-10 1
>10 2
marked 3
Hypertrophic fibres 1-10 1
>10 2
table 1 List of abnormal findings that may be found in the studied muscle biopsies, contributing to
the Morphological Abnormality score (table 3). In cases with 3 or more abnormal fibres, the
score is increased to 2.
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percutaneous needle biopsies (25-30 mg). Fragments were attached
on the bottom of a culture dish containing proliferation medium and
cultured at 37°C 9. After 7 to 10 days the myoblasts were plated out on
glass coverslips, proliferated further and than allowed to differentiate
into polynucleated myotubes for 7 days. The free cytosolic Ca2+
concentration ([Ca2+]i) of myotubes was determined after exposure to
increasing concentrations of halothane (0.11, 0.22, 0.44, 1.0, 2.0, 4.0,
8.0, 12.0 mM); for each concentration fresh myotubes were used.
[Ca2+]i on-line ratio measurement and calibration were performed
using a spectrofluorophotometer; the myotubes were loaded with
Fura-2. To verify the halothane concentrations, samples were 
determined using a head space gas chromatographic technique 9.
Results
Clinical examination found no evidence of neuromuscular disorders
and no incidents had been recorded during previous anaesthesia in
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Tension in mN Threshold concentration
Pat. Number Caffeine Halothane Caffeine Halothane IVCT
at 2mM at 0.44mM (mM) (mM) Status
I 0 0.5 32 - MHN
II:2 0.5 0 4 - MHN
IV:1 0 0.5 32 0.66 MHN
V 9 7.5 1 0.22 MHS
V:1 0 1 32 0.66 MHN
V:2 3 10 2 0.11 MHS
V:3 3 30 2 0.11 MHS
V:4 7.5 11 1 0.22 MHS
V:5 0 0 32 - MHN
VI 10 8 1 0.44 MHS
VI:1 4 12 1.5 0.11 MHS
VI:4 3.5 32 2 0.11 MHS
VI:5 3 6 0.5 0.22 MHS
VII 1.5 1.5 3 - MHN
VIII 0 0 32 - MHN
IX:1 12 14 1 0.22 MHS
IX:2 0 0 32 - MHN
IX:3 15 4 0.5 0.44 MHS
X - - - - MHE
X:2 0.5 5 4 0.22 MHE
XI 22 15 1 0.22 MHS
XI:1 10 12 1 0.22 MHS
XI:2 28 14 1 0.11 MHS
XII 0.5 0 4 - MHN
table 2 IVCT data
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this population of patients.
After exposure of muscle bundles to caffeine and halothane in the
IVCT, patients were classified according to the diagnostic criteria4. A clear
negative result (MHN) was found in muscle specimens of 9 individuals.
13 Relatives were designated MHS and 2 were designated MHE because
muscle specimens reacted abnormally to halothane only (table 2).
CK measurement showed significant differences between MHS (n=
13) and MHN (n=6) individuals, respectively 198± 189 and 68± 15
(mean±SD); p=0.03 (table 3).
Histological examination showed abnormalities in all muscle speci-
mens except in those from 2 MHN individuals (table 3). The mean
morphological abnormality (MA) score of the 13 MHS individuals (mean
±SD: 4.8±2.3) is significantly different from that of the 9 MHN indi-
viduals (1.7±1.4); p=0.001. Under light microscopy we observed cores in
muscle fibres of 6 individuals (5 MHS and 1 MHE); the cores were iso-
lated lesions in the individual fibres. In the MHS group, no correlation
could be demonstrated between IVCT results, CK, MA-score and/or 
the detection of cores. 
In this family linkage was detected to the RYR1 candidate region
on chromosome 19. The expected maximum lod score at a recombina-
tion fraction of q=0.01 for this pedigree was +3.98 (average lod score:
2.37, SD± 1.13) (figure 2) 10.
However, no mutation was detected which segregated with MH
susceptibility in the family following analysis of the three hotspot-regions
in the RYR1 gene containing the causative MH and CCD mutations 11.
Halothane produced a dose-dependent increase of the free
cytosolic Ca2+ concentration [Ca2+]i of all cultured myotubes (figure 3).
The Ca2+ response in MHS individuals proved significantly different from
that of control individuals with no overlap beyond 0.5 mM halothane.
Discussion
The past three decades have seen an immense increase in our under-
standing of MH, its clinical presentation 12, its pathophysiology 13 and
its molecular basis 6. However, screening for MH susceptibility remains
a difficult problem to solve. The presentation of an MH reaction can
vary enormously and there is no unique clinical sign of MH.
Individuals who are susceptible for MH often have no clinical or 
histological evidence of a muscle disorder. Many diagnostic tests have
been described but are now obsolete for MH screening because they
failed to discriminate sufficiently between MHS and MHN 14. Despite
significant difference between mean values of MHN and MHS individuals
after CK measurements and MA scoring in histological examination,
the lack of sensitivity prevents the introduction of these procedures
into clinical practise 15, 16. In selected MH-families an elevated CK
increases the probability of MHS from 50% (on the basis of family
history alone) to 94% 15, 17. In this family the risk of MHS increased to
92%. However, in patients with no clinical or family history of MH, CK
is of no value as a screening test for MH 15, 18. The observation of cores
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also increased the probability of MHS in this family, though this
histopathological finding, without clinical problems, has little 
diagnostic value in the general population.
What remains for detection of susceptibility to MH in probands 
is the standard caffeine halothane IVCT. Validated against the clinical
presentation, the sensitivity and specificity of IVCT results can best
guarantee patient safety during anaesthesia 19. Unfortunately, the IVCT
has several limitations; it requires large muscle samples (surgically
collected), it must be performed within 5 hours of the removal of
tissue and it is a technically demanding test that requires expertise.
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Pat. Nr Age IVCT result M/F CK IU/L MA-score Cores
I 68 MHN F 41 4 -
II:2 31 MHN M 66 0 -
IV:1 43 MHN F 84 0 -
V 56 MHS M 100 4 +
V:1 33 MHN F 78 1 -
V:2 33 MHS F 65 6 +
V:3 28 MHS M 265 2 -
V:4 27 MHS M 782 6 -
V:5 19 MHN M - 1 -
VI 58 MHS F 128 9 +
VI:1 41 MHS F 291 2 +
VI:4 31 MHS M 211 5 -
VI:5 30 MHS F 145 8 +
VII 53 MHN F - 2 -
VIII 52 MHN M 75 4 -
IX:1 36 MHS M 187 3 -
IX:2 32 MHN F 63 1 -
IX:3 30 MHS M 134 7 -
X 45 MHE M 144 6 +
X:2 26 MHE M 65 4 -
XI 50 MHS F 61 5 -
XI:1 30 MHS F 104 1 -
XI:2 28 MHS F 98 5 -
XII 44 MHN F - 2 -
Mean MHS (n = 13) 198 4.8
SD 189 2.3
Mean MHN (n = 9) 68 1.7
SD 15 1.4
p-value 0.03 0.001
table 3 MA-score and CK measurement results related to age, gender and IVCT result. The MA-score 
of the biopsy is the number obtained by summation of scores belonging to the defined
abnormal findings in the biopsy. Normal CK level < 90 IU/L
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Indeed, the IVCT is only available in 22 MH investigation centres across
Europe. An important diagnostic disadvantage of the IVCT is that it is
not absolutely specific 20, 21. Research studies in which respectively
cultured myotubes and an in vivo metabolic test have been used, may
have the potential for development as less invasive diagnostic tests;
they need to be validated with large numbers to define 
sensitivity and specificity9, 22. Despite extensive screening of the RYR1
gene, we were unable to identify any known or new mutations that
may underlie MHS in this family. Nevertheless, we have been able to
confirm linkage of the MHS locus with chromosome 19 markers around
RYR1. This means that we may still be able to apply genetic testing for
MHS among other members of this family to complement IVC-testing,
according to recently issued EMHG guidelines 11.
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figure 2 Graphical representation of two-point lod scores generated for the RYR1 region of
chromosome 19q.
Data is presented in a format generated in LODVIEW EXCEL in which each chromosomal graph
represents 2 point lod score data from specific microsatellite markers spaced at ~11cM intervals
along the chromosome 10. Shaded bars represent two-point lod score values at q = 0.02 for
specific markers. Line distributions for each bar represent lod score values from q = 0 (peak)
to q = 0.2 (termini). The y axis is graduated in ± 2 lod score intervals (+4 to -10), the stippled
line denoting the -2 lod score threshold for exclusion of linkage. The physical relationship of
the markers on the chromosome is shown above the genetic LODVIEW map
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Perspectives
Well documented and IVCT-phenotyped MH families showing linkage
between their MHS trait and RYR1, but not carrying any of the almost
30 mutations described in this gene, will encourage future inter-
disciplinary research between anaesthetists, geneticists and basic 
scientists to solve the puzzle of this heterogeneous disorder. In the
meantime, further elucidation of the mechanism of pathogenesis will
continue to improve the safety of patients susceptible to MH or with
related muscle disorders, who need to undergo anaesthesia.
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figure 3 Halothane induced, dose-dependent increase of [Ca2+]i in cultured skeletal muscle cells from
6 MHS individuals (n = 42: solid dots and line) and 4 control individuals (n = 32: open dots
and dotted line). Discrimination between MHS and control is 100% beyond 0.5 mM
halothane (p < 0.05)
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Chapter 6
general discussion
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‘Malignant hyperthermia’ has been recognised as an anaesthesia-related, potentially
life-threatening, genetic disorder since the mid-1960s. The combination of
halothane and succinylcholine in routine general anaesthesia revealed an 
abnormality in the calcium release channel of skeletal muscle sarcoplasmic 
reticulum (the ryanodine receptor) as the cause of MH. Malignant referred to 
dramatic case descriptions that had a fatal outcome in approximately 80%.
Hyperthermia was the most impressive clinical feature, describing patients who
became very hot and sweaty. Nowadays the term malignant hyperthermia is 
a misnomer. Better monitor facilities, in particular measuring end-tidal CO2, 
indicate hypermetabolism well before the core temperature begins to rise.
Increased awareness of MH by anaesthetists and dantrolene have contributed
greatly to the drop in mortality to almost zero. Due to its major symptoms, 
other conditions, syndromes or disorders have been associated with MH. However,
clarification of MH pathogenesis has made it possible to rule out almost all of
these MH-associated conditions or myopathies (e.g. heatstroke, sudden infant
death syndrome, neuroleptic malignant syndrome, myotonic disorders and 
muscular dystrophies).
MH presents with multiple non-specific clinical signs and laboratory findings. 
The latter relate to skeletal muscle hypermetabolism and ischemia. These ‘clinical
indicators’ observed during an acute anaesthetic reaction can be scored using the
MH clinical grading scale to determine the qualitative likelihood that the adverse
anaesthetic event actually represents MH. The MH clinical grading scale has been
recommended for use as an aid to an objective definition of MH. In actual practice
it is hampered by incomplete clinical information, which is a common situation.
In recent years the “incidence” of clinical MH has tended to decrease because of
increased use of regional anaesthesia and total intravenous anaesthesia (TIVA),
both “MH safe” techniques, together with a decrease in the use of succinyl-
choline. As the combination of succinylcholine and potent inhalational anaesthetic
agents produces a more profound MH reaction, the signs of MH are now often less
pronounced and can occur insidiously. Mild forms of MH could therefore be
missed. However, fulminant classical MH reactions do still occur.
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MH is a rare disease. The frequency of clinical MH, is therefore not easy to estimate.
The highest incidence of clinical MH that has been reported is 1 in 100, where MH
was defined as ‘masseter muscle rigidity’ in a study of children when only
halothane and succinylcholine were used for anaesthesia. However, in surveys of
mixed surgical populations fulminant MH has occurred in 1 in 200,000 to 250,000
anaesthetics. Several factors are responsible for this wide disparity in estimated
incidence, including: the definition of MH; the anaesthetic procedure and the
agents that were used; and the age and sex of the patients. The incidence of MH
is generally agreed to be 1 in 10.000 to 15.000 anaesthetics.
Some questions remain unsolved despite a good understanding of MH pathogenesis:
why does the incidence of clinical MH decrease with increasing age? Why is it most
commonly seen in the 10-30 age group? Why are males affected more frequently
than females? What is the impact of stress? Why do patients carrying a ‘risk allele’
not always develop MH during trigger anaesthesia? These phenomena could be
explained if clinical MH is triggered only when a combination of various factors
together disturb calcium regulation in the skeletal muscle cell.
Abnormalities in the calcium release channel of skeletal muscle sarcoplasmic
reticulum (SR) have been implicated as the central factor in the cause of the MH
syndrome. Succinylcholine and all potent inhalational anaesthetics are able to
induce MH episodes by increasing the rate of Ca2+ release from the SR. Potent
inhalational anaesthetics may interact with ‘risk variants’ of the SR calcium
release channel (ryanodine receptor) to induce an abnormal increase in the
release of Ca2+. This may be further aggravated by the destabilisation of
Ca2+-sensitive intracellular regulatory mechanisms believed to result from expo-
sure to potent inhalational anaesthetics. 
A lot of effort has been, and is being made to design diagnostic tests for MH-
susceptibility (MHS). While this research has helped our understanding of excitation-
contraction coupling, no test so far developed has been sufficiently reliable or
generally applicable to replace the caffeine-halothane in vitro contracture test
(IVCT). The IVCT is a biological test that measures muscle contracture upon exposure
to triggering (anaesthetic) agents. Actually, the IVCT could be seen as a surrogate
for the clinical scenario, because abnormal muscle contractures observed in vitro
reflect the alterations that occur in the patient. The IVCT, however, is invasive,
time consuming and it is a technically demanding test that requires expertise.
A test based on cultured muscle cells obtained by percutaneous needle biopsy is
less invasive and is easily reproducible. Halothane produces a dose-dependent
increase of the intracellular calcium concentration in cultured human skeletal
muscle cells. The calcium response in MHS individuals proved significant different
from that of control individuals. The time between biopsy and performance of the
test is not critical, because cell cultures can be expanded, frozen and thawed. 
In contrast IVCT requires large muscle samples (surgically collected) and must be
performed within 5 hours. More studies, comparing data from IVCT and cultured
cells have to be undertaken to determine sensitivity (and specificity).
A second alternative test that could have the potential for development as a less
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invasive diagnostic procedure is an in vivo metabolic test. Intramuscular injection
of halothane or caffeine leads to a local hypermetabolic reaction with concomitant
local increase in pCO2 in MHS individuals that is significantly higher than in normal
controls. This test will require large numbers of patients and controls to be studied
in a multicentre trial to define sensitivity and specificity.
MHS was first linked to the gene encoding the skeletal muscle ryanodine receptor
(RYR1) on chromosome 19q13.1 in 1990. It was thought that a genetic test for MH
was within reach, but the large size and complex nature of the RYR1 gene has made
identification of RYR1 mutations difficult. More than 80 individual mutations in
RYR1 have been detected to date in patients with MH and the associated myopathy,
central core disease (CCD). However, there is no prevalence of particular mutations
in all populations, and many mutations have been found only in single families.
Linkage studies have indicated that variations in other genes located elsewhere in
the human genome can also give rise to susceptibility to MH. Actually, MHS shows
a high level of genetic heterogeneity, the proportion of cases not linked 
to RYR1 (designated as the MHS1 locus) may be as high as 50%. To date, six loci,
including RYR1, have been identified as containing potential candidate MHS genes.
Because of this heterogeneity it is not as yet generally feasible to diagnose or to
exclude susceptibility to MH, on the basis of molecular genetic testing alone.
However, there are specific situations where detection of susceptibility to MH
using molecular genetic techniques can replace IVCT. Clinical practitioners and
geneticists of the European MH Group (EMHG) have agreed on guidelines for DNA-
based investigation for the sake of the safety of MHS patients and their families
who need to undergo anaesthesia. The original (2001) guidelines contained 15
RYR1 mutations for genetic testing. Once one of these causative mutations has
been detected in the proband, whose MHS status has been confirmed by IVCT, it
can be used to test relatives. Mutation carriers should consequently be regarded
as susceptible to MH, although confirmation of this diagnosis can only be carried
out by the IVCT.
Recently, a further 7 RYR1 mutations have met the EMHG criteria for their use in
predictive genetic testing. Mutations will be add to the list only after genetic and
functional characterization. The criteria that will need to be met are: 1) a full
description at the DNA and protein level; 2) co-segregation of the allele with MHS
and/or CCD in at least 2 pedigrees; 3) absence of the sequence change in 100 control
samples for exclusion of polymorphisms; and 4) the effect of the mutation on RyR1
function has been confirmed by recombinant in vitro expression or in ex vivo tissues.
In the meantime, the search for novel mutations in RYR1 goes on. Leukocytes seem
to be an adequate substitute tissue for screening the RYR1 gene. Leukocytes can
simply be isolated from human blood and used for extraction of RNA and reverse
transcription of messenger RNA into cDNA. Since the sequence of full-length
leukocyte RYR1 cDNA were shown to be identical to the sequence of human muscle
RYR1 cDNA, a standard, ‘noninvasive’, 10 ml blood sample is sufficient to allow a
rapid search for new mutations. 
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Despite the arrival of new diagnostic tests, contracture testing remains the only
reliable means of ascertaining MH status. Standardization of the IVCT has led to
the development of 2 essentially similar protocols in Europe and in North America.
Diagnosis of MHS has been achieved successfully with the standard caffeine-
halothane IVCT; but with any in vitro pharmacological test, such as the IVCT, there
is always going to be some overlap in results between true positives and true
negatives. In the interest of patient safety and from an anaesthesiological point
of view, the major role of a clinical MH investigation unit should be to exclude the
diagnosis of MH rather than to confirm it. In this way, patients and their entire
families are not falsely identified as MH-susceptible. However, the inevitable 
consequence of the need to avoid false negative results (sensitivity), is that a 
considerable number of false-positive results will be made. Multi-centre evaluation
showed a high diagnostic sensitivity of the IVCT in Europe: 99%, and in North
America: 97%; a satisfactory specificity in Europe: 94% and a low specificity in
North America: 78%. 
While it may not be possible to improve sensitivity, we should aim to minimise
the number of false positives. Our diagnostic procedure must be adequately
specific, otherwise anaesthesia will be made unnecessarily complicated and
expensive. In addition, the power of the molecular genetic studies could be
increased by improving the specificity of the IVCT.
The addition of other, potentially more specific, test agents to the standard 
caffeine-halothane IVCT could increase its reliability. Ryanodine and 
4-chloro-m-cresol have proved to be useful in improving reliability of MH 
diagnosis, although further studies should determine the sensitivity and 
specificity of both tests before inclusion into the standard IVCT protocol.
Unfortunately, with the addition of more test agents, we have automatically
created more MH-equivocal (MHE) categories. Since this MHE group contains a
high percentage of ‘false positive’ test results, the specificity is likely to decrease.
An important comment on the determination of sensitivity and specificity of the
IVCT includes the selection of patients. Both the European and the North American
MH Groups applied the MH Clinical Grading Scale to identify case subjects. Only
cases ranked as “almost certain to be MH susceptible” (MH rank D6 with a score of
50 or more) were accepted for inclusion into the studies, whereas investigation
with IVCT in most MH investigation centres is done from MH rank D4: “somewhat
greater than likely to be MH susceptible”. Latter comment mainly regard specificity.
In spite of the above-mentioned problems, the standard caffeine-halothane 
IVCT remains the cornerstone in the diagnostic procedure for patients who had
survived MH reactions. Patients and their relatives who are “labeled” MHS or 
MHE by the IVCT should never be placed in a “triggering” environment.
Other important parts of the procedure are a clinical examination, measurement
of serum creatine kinase activities and a histological examination of the muscle
biopsy, to exclude an underlying muscle disease which could account for the
adverse anaesthetic event. Genetic analysis can not yet replace contracture test-
ing, and may remain impractical due to the complexity of the genetics of MH.
Further research needs to be done before an in vivo metabolic test or a test on
cultured skeletal muscle cells can replace the invasive in vitro contracture test.
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Malignant hyperthermia (MH), a potentially fatal adverse reaction during or after
an operation was first recognised as an anaesthetic-related complication in 1960.
It was not until 1985 that international researchers agreed upon a protocol for 
the diagnosis of MH susceptibility. MH has undergone an explosion of infor-
mation since.
The aim of this thesis is to study the diagnostic procedures for MH susceptibility,
with special emphasis upon refining the biological diagnostic test and developing
a new test. By this and by improving protocols and guidelines for investigation of
susceptibility to MH, we have gained confidence in the diagnosis “MH suscep-
tible (MHS)”. 
Chapter 1 reviews the present knowledge of MH. Historical aspects of MH will 
be adjusted to results of pathophysiological and genetics research. In humans
genetically predisposed to MH, anaesthesia with succinycholine and/or volatile
anaesthetics can induce an MH reaction. Unfortunately there is no one symptom
or sign that is unique to MH, and MH is not one entity. The clinical diagnosis of
MH is made on the combination and the severity of abnormal signs, metabolic
and muscular in origin. The type of clinical presentation sets the treatment of an
MH reaction. Prompt dantrolene injection is the cornerstone of effective MH therapy,
time is of the essence and morbidity is correlated with the duration of symptoms.
True incidence of MH is unknown because of the variable clinical presentation.
The incidence is estimated to be 1 in 10,000 to 1 in 225,000 anaesthetics.
The crucial role in the pathogenesis of MH is elevated myoplasmic calcium.
Abnormalities in the calcium release channel of skeletal muscle sarcoplasmic
reticulum (the ryanodine-dihydropyridine receptor complex) have been implicated
in the cause of MH. Genetic linkage analysis in human families with MH have
indicated that a mutation in the ryanodine receptor gene (RYR1) could account
for susceptibility to MH. The RYR1 locus is located on chromosome 19.
Clarification of MH pathogenesis has made it possible to rule out MH-associated
conditions or myopathies. The only clearly associated muscle disorder is central
core disease.
Chapter 2 describes the in vitro contracture test (IVCT). The IVCT determines the
sensitivity of freshly obtained skeletal muscle specimens to several test agents. It
has generally been accepted as “the gold standard” to determine the susceptibility
to MH. European MH investigation units, forming the European Malignant
Hyperthermia Group (EMHG), agreed upon a standardised protocol in 1984. 
This protocol contains the diagnostic criteria.
To determine the sensitivity and specificity of the IVCT, the results of IVCT in 1502
patients with previous fulminant MH were collected from 22 centres of the EMHG.
Of these 1502 probands, 119 had clinical scores of 50 and above in the Clinical
Grading Scale to predict MH susceptibility such scores describing a likelihood of
MH as “almost certain”. By comparing IVCT results from these 119 probands with
those of 202 low-risk individuals, a diagnostic sensitivity of the IVCT of 99.0% was
observed if the MHE group (MH equivocal: muscle specimens only react abnormal-
ly to halothane or caffeine) is considered susceptible. Accompanying specificity
was 93.6%.
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Halothane, one of the test agents in the IVCT, has been replaced by sevoflurane 
in modern anaesthesia because of favourable characteristics. In this chapter the 
in vitro effects of sevoflurane are described. Sevoflurane can trigger an abnormal
contracture in muscle from MH susceptible patients in vitro; the threshold concen-
tration measures 7% or 0.70 mmol/l. This is indicative of malignant hyperthermia
susceptibility. Exposure to sevoflurane should be avoided in patients thought to
be susceptible to malignant hyperthermia.
Chapter 3 describes a study to investigate the usefulness of cultured skeletal 
muscle cells, obtained by percutaneous needle biopsies, for determining MH 
susceptibility. Muscle samples from 6 MHS patients and from 4 controls were used
to culture myotubes. The free cytosolic calcium concentration ([Ca2+]i) of myotubes
was determined after exposure to halothane. The dose-dependant calcium
response in cultured muscle cells of the MHS individuals is significantly different
from that of the control individuals after exposure to halothane. There is no overlap
beyond halothane concentrations ≥ 0.5 mmol/l. Cultured human muscle cells,
obtained from needle biopsies, may well be applied in alternative and less invasive
diagnostic tests for MH susceptibility. More multi-centre studies, comparing data
from IVCT and results from tests using cultured cells, have to be undertaken to
determine sensitivity.
In chapter 4 the diagnostic procedures in four European MH centres have been
evaluated to see how they deal with the referral of patients and how this is
reflected in workload and funding. The 4 national MH investigation units in
Belgium, the Netherlands, Switzerland and the United Kingdom select probands
for screening in a similar but individual way based on experience. The number 
of referrals was too low to demonstrate inter-centre difference between IVCT 
indication criteria and IVCT results. This study provided an insight into the need
for further standardisation and quality assurance for the diagnosis of MH. A
European quality assurance project has been started, based on an independent
on-site visiting programme to all 22 European MH investigation units. This project
will improve confidence in the diagnostic screening for MH susceptibility.
Ultimately it will improve the safety of MH susceptible patients and their 
families, who need to undergo anaesthesia.
In the second part of chapter 4, the European guidelines for the detection of MH
susceptibility using molecular genetic techniques are presented. The main purpose
for drawing up the present guidelines was to avoid false MH-negative (MHN)
diagnoses because of the potential risk of MH during general anaesthesia for
these patients and their blood relatives. At this stage molecular genetic testing 
for 22 causative mutations in the ryanodine receptor gene (RYR1) of the index case
could lead to quicker results for the rest of the kinship. An up-to-date list of
mutations that have been shown to directly alter RYR1 caffeine or halothane 
sensitivity is shown on the following website: http://www.emhg.org.
Chapter 5 is a survey of three decades of screening for MH in a Dutch family. 
24 relatives of a patient who died in 1973 after suffering MH have been studied 
in detail. All steps of the screening procedure, follow developments in testing for
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the diagnosis of MH susceptibility from 1984 until 2002. Linkage analysis implicated
RYR1 on chromosome 19q13.1 as the disease susceptibility locus in the family.
Unfortunately, following analysis of the three hotspot-regions in the RYR1 gene
containing the causative MH and CCD mutations, no mutation was detected 
which segregated with MH susceptibility in the family. 
Histological examination and CK measurements showed significant differences
between MHS (n= 13) and MHN (n=6) individuals. Despite significant difference
between mean values of MHN and MHS individuals that belong to this family, 
the lack of sensitivity in the general population prevents the introduction of these
procedures into screening for susceptibility to MH. In this family the IVCT remains
the gold standard for diagnosis of susceptibility to MH.
Chapter 6 contains the general discussion. Nowadays the term malignant
hyperthermia is a misnomer. Better monitoring facilities, in particular measuring
end-tidal CO2, indicate hypermetabolism well before the core temperature begins
to rise. Increased awareness of MH by anaesthetists and the availability of dantro-
lene have contributed greatly to the drop in mortality to almost zero.
MH is a rare disease. In recent years the “incidence” of clinical MH has tended to
decrease because of increased use of regional anaesthesia and total intravenous
anaesthesia (TIVA), both “MH safe” techniques. However, whilst succinylcholine
and potent inhalational anaesthetic agents are being used MH reactions will still
occur, and as a consequence there is the need to identify individuals who are
susceptible to MH. Since MH is inherited as an autosomal dominant condition,
diagnosing MH susceptibility is a matter of family concern. 
Whenever an “MH reaction” occurs in a patient that is exposed to triggering
drugs, all available clinical signs should be analysed to predict the MH likelihood.
Through such analysis, together with a personal or family history suggestive of
MH, probands are selected for screening. If the proband has died then the nearest
appropriate relatives should be screened. The lowest age limit for the muscle
biopsy is 12-14 years as IVCT results have been inconclusive below this age. Despite
the arrival of new diagnostic tests, contracture testing remains the only reliable
means of ascertaining MH status. The IVCT, however, is invasive, time consuming and
a technically demanding test that requires expertise. There are specific situations
where detection of susceptibility to MH using molecular genetic techniques can
replace the IVCT. Clinical practitioners and geneticists of the European MH Group
(EMHG) have agreed on guidelines for DNA-based investigation for the sake of
the safety of MHS patients and their families who need to undergo anaesthesia.
Further research needs to be done before an in-vivo metabolic test or a test on
cultured skeletal muscle cells can replace the invasive in-vitro contracture test,
which has a sensitivity of 99% in Europe. This research will require large numbers
of patients and controls to be studied in a multi-centre trial to determine 
sensitivity and specificity.
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Samenvatting
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Maligne hyperthermie (MH) een zeldzame potentieel dodelijke reactie tijdens 
of na een operatie, werd voor het eerst als anesthesiecomplicatie onderkend in
1960. Rond 1985 werd de methode beschreven om MH-risicodragers op te sporen
waarover internationaal overeenstemming bestond. Sindsdien zijn de inzichten
over MH danig gewijzigd. De doelstelling van het onderzoek in dit proefschrift is
tweeledig. Enerzijds werden de diagnostische procedures van de afgelopen 25 jaar
bestudeerd en geëvalueerd. Anderzijds werden de bestaande diagnostische tests
verfijnd en werden nieuwe tests ontwikkeld. Dit heeft geleid tot verbetering van
onderzoeksprotocollen c.q. verhoging van de betrouwbaarheid van de diagnose
‘gevoelig voor maligne hyperthermie’ (MHS).
Hoofdstuk 1 geeft een overzicht van de huidige kennis over MH. Historische 
veronderstellingen worden bijgesteld naar aanleiding van nieuw verworven
pathofysiologische en genetische feiten. Een maligne-hyperthermiecrisis treedt
op bij daarvoor gevoelige personen tijdens algehele anesthesie als reactie op 
toediening van succinylcholine en/of gehalogeneerde inhalatieanaesthetica.
Helaas bestaat er geen klinisch kenmerk dat uniek is voor MH. Een MH-reactie 
kan zich verschillend presenteren, afhankelijk van de ernst van de metabole
stoornissen en de mate van spierbeschadiging. De klinische presentatie bepaalt
welke therapeutische maatregelen dienen te worden genomen om verdere schade
te voorkomen. Hoeksteen van behandeling van een MH crisis is zo snel mogelijk
dantroleen intraveneus toedienen. 
De precieze incidentie van MH is niet te berekenen omdat er een zeer gevarieerde
presentatie is. Schattingen lopen uiteen van 1 op 10.000 tot 1 op 225.000 
anesthesieën.
MH berust op een defect in het ryanodine-dihydropyridine receptorcomplex,
gelokaliseerd in het sarcoplasmatisch reticulum in de skeletspiercel. Onder
bepaalde omstandigheden tijdens anesthesie geeft dit aanleiding tot een 
abnormale regulatie van de myoplasmatische calciumconcentratie. Door middel
van koppelingstudies is bij enkele families een verband aangetoond tussen
mutaties in het ryanodinereceptor-gen (RYR1) en gevoeligheid voor MH. Dit RYR1 
is bij de mens gelokaliseerd op chromosoom 19.
Met de ontdekking van de oorzaak van gevoeligheid voor MH, maar ook doordat
meer bekend is geworden over de oorzaken van neuromusculaire ziekten en 
syndromen met temperatuursontregeling, kunnen we MH tegenwoordig onder-
scheiden van andere aandoeningen. Alleen central core disease (CCD) en MH lijken
nog een zelfde oorzaak te kunnen hebben met overlap in klinische kenmerken.
Hoofdstuk 2 beschrijft de in vitro contractuur test (IVCT). Deze biologische test
waarbij vers gebiopteerd skeletspierweefsel wordt blootgesteld aan verschillende
teststoffen geldt sinds 1984 als de gouden standaard voor diagnostiek naar
maligne hyperthermie gevoeligheid. De IVCT wordt uitgevoerd volgens het protocol
van de European Malignant Hyperthermia Group (EMHG), een samenwerkings-
verband van alle Europese maligne hyperthermiecentra. In dit protocol zijn de 
criteria voor de diagnose vastgelegd.
Als Europese groep hebben wij de sensitiviteit en de specificiteit van de IVCT
bepaald. Hiertoe werden 1502 patiënten onderzocht die allen een IVCT ondergingen
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nadat bij hen een maligne hyperthermiereactie was opgetreden. Bij 119 van deze
1502 maligne hyperthermieprobandi kon op voorhand de diagnose “MH bijna
zeker” gesteld worden omdat op grond van de ‘klinische graderingsschaal voor
MH’ een puntenwaardering van ≥ 50 punten werd toegekend aan de ernst en aard
van symptomen. De IVCT-resultaten van deze 119 van MH verdachte patiënten 
werden vergeleken met die van 202 controlepatiënten. Hieruit hebben wij een
diagnostische sensitiviteit berekend van 99.0% waarbij we de groep patiënten die
in de IVCT slechts op 1 van de 2 teststoffen positief reageerde (MHE) als ‘gevoelig
voor MH’ hebben beschouwd. De specificiteit van de IVCT hierbij bedroeg 93.6%.
Omdat halothaan, één van de teststoffen in de IVCT, in de hedendaagse anes-
thesiologische praktijkvoering nagenoeg geheel vervangen is door sevofluraan 
en omdat de MH-reacties van de laatste jaren veelal na toediening van sevo-
fluraan zijn opgetreden, beschrijven wij in dit hoofdstuk de uitkomst van een
studie naar de in-vitro effecten van sevofluraan. Spierweefsel van individuen 
met de diagnose MHS reageerde eveneens positief op sevofluraan. Anesthesie met
gebruikmaking van sevofluraan bij deze mensen moet dus te allen tijde worden
voorkomen. De verdamperconcentratie van de sevofluraan werden vergeleken met
de sevofluraan-concentraties in de vloeistoffase. Hierdoor waren we in staat de
sevofluraan drempelwaarde vast te stellen bij een contractuur van ≥ 2 mN: 7% of
0.70 mmol/l.
Hoofdstuk 3 beschrijft de studie waarin wij onderzocht hebben of gekweekte
skeletspiercellen kunnen worden aangewend om gevoeligheid voor MH aan te
tonen. Spiercellen uit de musculus quadriceps femoris, verkregen door middel 
van een naaldbiopsie, werden opgekweekt tot myotubes. Deze myotubes werden
vervolgens blootgesteld aan halothaan, waarbij de intracellulaire calciumconcen-
tratie ( [Ca2+]i ) werd gemeten. Vergelijking van de resultaten van myotubes
gekweekt uit spierweefsel van 6 MHS individuen met die van 4 controlepersonen
gaf, als reactie op toediening van halothaan, een dosis afhankelijke stijging te zien
van de [Ca2+]i. Bij een halothaanconcentratie ≥ 0.5 mmol/l wordt er geen overlap
meer waargenomen. De beschreven methode zou een alternatieve diagnostische
test voor het aantonen van gevoeligheid voor MH kunnen zijn met als voordeel
dat het minder invasief is dan de IVCT. Vervolgstudies en multicentre studies zijn
nodig om de sensitiviteit van de test te bepalen.
Hoofdstuk 4 bevat een studie waarin de diagnostische procedures in 4 Europese
MH centra zijn geëvalueerd en met elkaar zijn vergeleken.
In de 4 nationale MH diagnostiek centra in België, Nederland, Zwitserland en
Groot-Brittannië worden verwijzingen van patiënten die van MH worden verdacht
op een verschillende manier afgehandeld. Het aantal onderzochte verwijzingen in
de studie bleek echter te klein om consequenties uit de verschillen in handelswijze
te trekken. De studie heeft wel mede de aanzet gegeven tot het opzetten van een
visitatieprogramma van alle Europese MH-centra. Kwaliteitscontrole van de IVCT 
en meer standaardisatie in de behandeling van verwijzingen komen de betrouw-
baarheid in de diagnose ‘gevoelig voor maligne hyperthermie’ (MHS), maar met
name ook in de diagnose ‘niet gevoelig voor maligne hyperthermie’ (MHN), in
heel Europa ten goede. Dit zal de veiligheid doen toenemen indien MHS patiënten
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en hun familieleden een operatie onder algehele anesthesie moeten ondergaan.
Het tweede deel van dit hoofdstuk is een weergave van de richtlijnen die door de
EMHG zijn uitgevaardigd voor het verrichten van MH-diagnostiek op moleculair
genetisch niveau. De richtlijnen (met een update in de appendix) zijn geschreven
als een dringend advies om deze te volgen omdat foutieve of onvolledige vertal-
ing van genetische bevindingen kan leiden tot klinische problemen met nadelige
gevolgen. Met name vals-negatieve resultaten van genetisch onderzoek kunnen
ernstige gevolgen hebben als deze mensen onder algehele anesthesie worden
gebracht met MH uitlokkende medicijnen. Diagnostiek naar gevoeligheid voor MH
op DNA niveau is mogelijk maar blijft beperkt tot families waarvan de MHS-
geteste individuen drager zijn van één van de 22 mutaties in het ryanodinerecep-
tor gen (RYR1) waarvan een oorzakelijk verband is aangetoond. Een up-to-date
overzicht is opvraagbaar op het internet (http://www.emhg.org).
Hoofdstuk 5 is een overzicht van 30 jaar diagnostisch onderzoek in een
Nederlandse MH-familie. 24 eerste- en tweedegraads verwanten van een patiënt
die in 1973 na een maligne-hyperthermiecrisis overleed zijn sinds 1984 onderzocht
op gevoeligheid voor maligne hyperthermie. De diagnostische procedure van deze
familie in de periode van 1984 tot 2003 evolueert met de ontwikkelingen van de
MH-diagnostiek in het algemeen. In de familie bestond voldoende bewijs dat
MH-gevoeligheid gekoppeld is aan het RYR1 gen op chromosoom 19. Echter,
ondanks grote inspanning kon er geen van de bekende mutaties worden aange-
toond in het RYR1 gen, noch kon een nieuwe mutatie worden geïdentificeerd.
Histologisch onderzoek en bepaling van de creatinekinase activiteit (CK) gaf
evidente verschillen tussen MHS- en MHN-individuen; doch beide onderzoeken
blijken te weinig sensitief voor een betrouwbare diagnose. Concluderend blijft
ook in deze familie de IVCT de ‘gouden standaard’ voor het aantonen van 
MH-gevoeligheid.
Hoofdstuk 6 bevat de general discussion. ’Maligne hyperthermie’ is inmiddels een
ongelukkige term. Patiënten overleven tegenwoordig nagenoeg altijd een MH-
reactie indien deze snel herkend wordt en er onmiddellijk adequaat gehandeld
wordt. Een serieuze MH-reactie openbaart zich namelijk doorgaans in een vroeg
stadium met stijging van het CO2 in de uitademingslucht, en is goed behandel-
baar d.m.v. dantroleen. Ernstige temperatuurontregelingen met een toename
boven 40 °C worden zelden of nooit meer gerapporteerd. MH is zeldzaam en een
MH-reactie zal steeds minder optreden of ‘subklinisch’ verlopen omdat de uit-
lokkende medicijnen in de moderne anesthesiologische praktijkvoering langzaam
maar zeker worden vervangen door medicijnen die geen MH-reactie uitlokken bij
patiënten die daarvoor gevoelig zijn. Echter, zo lang er nog succinylcholine of
gehalogeneerde inhalatieanaesthetica (halothaan, isofluraan, enfluraan, sevoflu-
raan en desfluraan) gebruikt worden, blijft het noodzaak om risicodragers op te
sporen. MH berust op een autosomaal dominant overervende aanleg: een mutatie
in het ryanodinereceptor gen. Diagnostisch onderzoek betekent dus screening van
de hele familie. Indien men bij een patiënt tijden anesthesie MH vermoedt en er
geen plausibele verklaring voor de verschijnselen gevonden wordt, komt de
patiënt in aanmerking voor nadere diagnostiek. Aan de hand van een analyse van
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de klinische kenmerken en persoonlijke en familiaire anamnestische gegevens,
wordt op voorhand het risico op vatbaarheid voor MH ingeschat om de indicatie
voor de IVCT te stellen. Als de ‘index case’ is overleden of jonger is dan 12-14 jaar
worden eerstegraads familieleden getest. De IVCT heeft het nadeel dat het een
invasieve test is die alleen bij volwassenen kan worden toegepast. De test is 
bewerkelijk en vereist veel expertise maar wordt desondanks wereldwijd erkend als
de meest betrouwbare test om MH-gevoeligheid aan te tonen. Moleculair genetisch
diagnostisch onderzoek naar gevoeligheid voor MH is verantwoord onder bepaalde
voorwaarden, binnen één familie. Van alternatieve tests voor de diagnostiek van
MH-gevoeligheid zoals een in vivo metabole test of een test op gekweekte
myotubes is de sensitiviteit nog onbekend; daar waar de sensitiviteit van de IVCT
in Europa 99% bedraagt.
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